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The overuse of antibiotics to treat cystic fibrosis (CF) lung infections has led to high 
levels of antibiotic resistance. Novel antimicrobial agents that could replace or 
complement current therapies are needed to fight chronic infections in CF patients. The 
advent of carbon monoxide-releasing molecules (CORMs) has been useful in 
investigating the physiological effects of CO by allowing the controlled release of CO to 
specific targets in mammalian systems. Recent evidence shows that the bactericidal 
activity of CORMs against a number of species is more effective compared to CO gas. 
Here, we applied ruthenium- based CORMs (CORM-2, CORM-3) and manganese-based 
CORM (PhotoCORM [Mn(CO)3(tpa-κ3N)]+) to biofilms using a novel nebulizer 
technique in conjunction with a Modified Robbins Device, and compared these effects 
with laboratory planktonic cultures of the Gram-negative pathogen Pseudomonas 
aeruginosa. We demonstrate that both CORM-2 and CORM-3 rapidly kill planktonic 
cells in laboratory culture. Although CORM-3 inhibits surface-associated growth of P. 
aeruginosa by both preventing biofilm maturation and killing bacteria within the 
established biofilm, cells growing in a biofilm are more resistant to CORM-3 than 
planktonic cells. The mechanisms behind the activity of CORM-3 resistance from P. 
aeruginosa biofilm cells are examined. Poor penetration and anaerobic 
microenvironment may contribute to this resistance, but not starvation. Aerosolized 
CORM-3 treatment has a similar bactericidal effect to aerosolized colistin, a commonly 
used antibiotic for P. aeruginosa lung infections. Although CORM-2 or colistin kills 
bacteria within the established biofilm, the combination effect of those two antimicrobial 
compounds was found to be only additive against P. aeruginosa planktonic cells and 
biofilm cells. Although activated PhotoCORM exhibits slightly inhibitory effect on P. 
aeruginosa planktonic cells, the compound significantly inhibits surface-associated 
growth of P. aeruginosa by both preventing biofilm formation and killing bacteria within 
the established biofilm. Anaerobic cultures of P. aeruginosa are less sensitive to CORM-
3 compared to aerobic cultures.  
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1.1 Carbon monoxide (CO) 
Carbon monoxide (CO) is a colourless, odourless and tasteless gas that is commonly 
considered as a poison and an atmospheric pollutant. The major source of CO in nature 
is generated by photochemical reactions in the troposphere (Weinstock and Niki, 1972). 
Other natural sources of CO natural combustion such as volcanoes and forest fires, and 
the incomplete oxidation of carbon-containing compounds during operating internal 
combustion engines, burning fossil fuels and iron smelting. Since Claude Bernard 
investigated the toxic effects of CO on dogs around 1846, its toxicity has been feared and 
exploited for centuries. The 2015 report from the All-Party Parliamentary Carbon 
Monoxide Group (APPCOG) has shown that around 40 deaths and 200 hospitalizations 
were caused by accidental carbon monoxide poisoning each year in England & Wales. 
Moreover, over 4,000 CO poisoning cases were treated in accident and emergency 
departments each year in England. 
 
CO is a small molecule (molecular mass of 28) containing one carbon atom and one 
oxygen atom. It is very stable due to a triple bond formation which is similar to dinitrogen 
(N2) and has a high bond dissociation energy of 1072 kJ mol-1. At room temperature CO 
exists as a gas owing to its low boiling point (-191.5 °C). However, CO is able to form 




Recent advances have classified CO as a gasotransmitter molecule that has important 
roles in biology. The gasotransmitter family also includes at present two other important 
biological molecules: nitric oxide (NO) and hydrogen sulfide (H2S) (Li et al., 2009, 
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Tinajero-Trejo et al., 2013). These three molecules have similar characteristics: they are 
all small, membrane-permeable, toxic molecules; they are produced endogenously in 
small amounts in mammalian systems; and they play vital roles in the body such as 
signalling and messaging. Each gasotransmitter is suggested to have potential in 
therapeutic applications (Bannenberg and Vieira, 2009, Szabo, 2010). 
 
1.1.2 CO in mammalian systems and bacteria 
High concentrations of CO have toxic effects in mammals due to its intrinsic high affinity 
for the ferrous iron of haemoglobin to form carbonmonoxy-haemoglobin (COHb), which 
prevents the delivery of oxygen to tissues (Goldbaum et al., 1975). Interaction of CO with 
other haem proteins causes structural modifications and alteration of their biological 
function that may also contribute to CO toxicity (Piantadosi, 2002). 
 
However, Tenhunen and workers attributed to the realization that CO is an endogenous 
product of haem metabolism by haem oxygenase (HO). The degradation of haem by HO 
requires O2 and NADPH. NADPH activates O2 and reduces Fe3+ in haem to Fe2+, which 
is necessary for the cleavage of haem. The breakdown of haem results in CO, Fe2+ and 
biliverdin (a green pigment) (Tenhunen et al., 1969), which is later broken down by 
biliverdin reductase into bilirubin (a yellow pigment) (Wu and Wang, 2005) (see Figure 
1.1). Haem breakdown can be visualized during bruising. Such an injury will initially 
appear purple-red as oxygenated haem is released under the skin. Haem oxygenase uses 
oxygen to break down haem, generating anaerobic conditions and therefore deoxyhaem, 
causing the bruise to appear blue. The formation of bilirubin will then lead to the bruise 
becoming yellow (Mann, 2012). 
 
Endogenously-produced CO has been shown to have various cytoprotective functions 
including roles as neurotransmitter (Verma et al., 1993), as a vasodilator (Furchgott and 
Jothianandan, 1991), and having anti-inflammatory (Otterbein et al., 2000) and anti-




Figure 1.1 Degradation of haem by haem oxygenase. Haem is broken down to 
biliverdin by HO while liberating a molecule of CO and Fe2+. Then biliverdin is rapidly 
converted to bilirubin in the presence of biliverdin reductase. Modified from Motterlini 
and Otterbein (2010).  
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In certain bacteria, CO is used as their sole carbon and energy source (Ragsdale, 2004). 
The metabolism of CO by some bacterial species has been comprehensively reviewed 
(King and Weber, 2007, Ragsdale, 2004, Oelgeschlager and Rother, 2008).  This process 
requires enzymes such as CO dehydrogenase (CODH), so CO can be oxidized to CO2 
and generates two protons and two electrons in metabolic pathways (as shown in equation 
(1)). 
CO + H2O → CO2 + 2H+ + 2e-       (1) 
 
The bacteria also have the ability to detect CO through protein sensors. One example is 
CooA from R. rubrum, which is a typical example of a haem-based CO sensor (Aono et 
al., 1996). It regulates the expression of CO-utilising genes (Shelver et al., 1995), 
including the coo operon (Bonam et al., 1989). Other examples include FixL in 
Rhizobium meliloti (Rodgers and Lukat-Rodgers, 2005, Gilles-Gonzalez et al., 1991), 
RcoM from anaerobic Burkholderia xenovorans (Kerby et al., 2008) and HemAT in B. 
subtilis (Hou et al., 2000). 
 
1.1.3 The therapeutic potential of CO 
As discussed in section 1.1.2, CO shows beneficial effects within mammalian systems, 
which has led to research into using CO for therapeutic purposes. This can be achieved 
by the induction of HO-1 expression or the inhalation of gaseous CO. Especially, CO 
inhalation therapy shows promising benefits as a natural compound that is not 
metabolized by the body to produce harmful breakdown products (Motterlini and 
Otterbein, 2010). Recently, several clinical trials were carried out for CO inhalation 
therapy. For example, one phase II trial investigated the use of air containing CO gas (100 
– 250 ppm) to prevent the development of postoperative obstructions of the bowel 
following colon surgery, while another investigated the use of CO to improve the success 
rate in kidney transplantation (reviewed by Mann, 2010). However, many questions must 
be answered before CO inhalation can be considered as a credible therapy. These include 
questions about the dose of CO required, and whether this is best delivered in multiple, 
low dose sessions, or in less frequent, larger doses (Motterlini and Otterbein, 2010). 
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1.2 Carbon Monoxide Releasing Molecules (CORMs) 
1.2.1 CORMs discovery and development 
With the increasing studies on the beneficial biological consequences of CO in the body, 
exploration of safe mechanisms to deliver CO into biological systems has begun. The 
advent of CO-releasing molecules allowed the possibility of storing CO in a solid form 
and then releasing CO in a controlled, targeted manner in the body (Motterlini et al., 
2002). These molecules provide a number of advantages over CO inhalation, such as 
overcoming the limitations associated with gaseous CO application and allowing 
controlled amounts of CO to be applied directly to tissues. 
 
Initially, Brian Mann and Roberto Motterlini considered using transition metal carbonyls 
to delivery CO and commercially available carbonyl compounds were shown to have 
some encouraging vasoactive properties in vivo. However, the problems caused by these 
commercial compounds included insolubility in water while some compounds required 
photolysis to release CO. Therefore, the development of CORMs to make them versatile 
for using in biology was required (Mann, 2012). In order to successfully use CORMs in 
biological systems, CORMs should be non-toxic, water-soluble, pure and stable, and 
release CO at adequate rates (Davidge et al., 2009a). The structure and properties of 
several commonly used CORMs are listed in Table 1.1, and the CORMs used in this 
thesis are described in more detail below. The potential for therapeutically using CORMs 
has been confirmed and the details will also be reviewed in this section. 
 
1.2.1.1 CORM-2 
CORM-2 (tricarbonyldichlororuthenium (II) dimer) is a ruthenium-based compound, 
which is insoluble in water but can be dissolved in DMSO. Motterlini and co-workers 
found that CORM-2 releases CO spontaneously by substitution of CO coordinated to 
ruthenium (Ru) with DMSO from the solvent. When dissolved in DMSO, the CORM-2 
dimer immediately dissociates to form tri-carbonyl and di-carbonyl monomers 
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(Motterlini et al., 2002). When CORM-2 solubilized in DMSO, CO is released to 
myoglobin at around 0.7 mol of CO per mol of the compound with a half-life of 
approximately 1 min (Motterlini et al., 2002). Further evidence suggests that sulfite 
species such as dithionite dramatically increase the release of CO from CORM-2 
(McLean et al., 2012). 
 
Since CORM-2 became commercially available, this compound has been widely studied. 
Several studies have confirmed that CORM-2 has beneficial effects in vivo. In human 
airway smooth muscle, CORM-2 inhibits proliferation of human smooth muscle cells by 
increased mitochondrial ROS production and decreased phosphorylation of ERK1/2 and 
cyclin D1 expression (Taille et al., 2005). In mice kidney, CORM-2 protects against acute 
renal failure caused by ischemia (Vera et al., 2005). CO from CORM-2 also promotes 
generation of reactive oxygen species (ROS) from complex III of the electron transport 
chain. This in turn leads to the redox state of key cysteine residues in human cardiac L-
type Ca2+ channels, inhibiting ion transport, which has cardioprotective effects (Scragg 
et al., 2008). In the liver of septic mice, CORM-2 reduces inflammation by attenuating 
LPS-induced production of ROS and NO by preventing expression of intracellular 
adhesion molecule-1 and activation of NF-κB (Cepinskas et al., 2008). In a transplant 
model, pre-treatment of the kidney donor rats with CORM-2 protects renal transplants 
from ischemia reperfusion injury by modulating inflammation (Caumartin et al., 2011). 
More recently, the protective effect of CORM-2 in a mouse model of acute pancreatitis 
has been reported. CORM-2 inhibits systemic inflammatory cytokines and decreases 
TNF- generation which resulted in reducing mortality, pancreatic damage and lung 
injury (Xue and Habtezion, 2014). 
 
1.2.1.2 CORM-3 
A major disadvantage of CORM-2 is its poor solubility in water. In order to solve this 
problem, Motterlini and colleagues successfully synthesised another ruthenium-based 
water-soluble compound tricarbonylchloro(glycinato)ruthenium(II), known as CORM-3 
(Ru[CO]3Cl(glycinate)). This compound releases 1 mole of CO per mole compound to 
myoglobin in vitro with a half-life of less than 2 min. (Clark et al., 2003). CORM-3 is  
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Table 1.1 The structure and properties of several commonly used CORMs. 
CORMs Chemical formula Structure Solubility CO release characteristics Reference 
CORM-1 [Mn2(CO)10] 
 
Soluble in DMSO Photolysis 
Stoichiometry of CO release has not been reported 
(Motterlini et al., 2002) 
CORM-2 [Ru(CO)3Cl2]2 
 
Soluble in DMSO Promoted by dithionite 
Releases 0.7 mole CO / mole CORM 
(Motterlini et al., 2002) 




Soluble in water Promoted by dithionite 
Releases 1 mole CO / mole CORM 
(Clark et al., 2003) (Foresti 





Soluble in water Releases 1 mole CO / mole CORM 
Half - life 20.2 min 
(Desmard et al., 2012) 
CORM-A1 Na2[H3BCO2] 
 
Soluble in water Releases CO spontaneously 
The rate is pH and temperature dependent 







Promoted by dithionite, pyridine and phosphorus 
ligands 
Release 1 mole CO spontaneously and ≤ 3.2 mole / 
mole CORM by ligand substitution 
(Crook et al., 2011) 







Soluble in water Promoted by irradiation at 365 nm 
Releases ≤ 2.2 mole CO / mole CORM 
(Nagel et al., 2014) 
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synthesised from CORM-2, with the addition of a glycine residue and a chloride 
coordinated to the ruthenium. Glycine was chosen as a preferable ligand as it does not 
contain a chiral centre, which avoids the formation of diastereomers (Mann, 2012). 
McLean and colleagues have explored in greater detail the mechanism of CO release in 
CORM-3 (McLean et al., 2012). In their view, reduced myoglobin alone was not 
sufficient to cause CO release from CORM-3, but that dithionite, or other sulfite species, 
greatly facilitated CO release. Therefore, endogenous sulfite species, or other similar 
intracellular components, trigger CO release in vivo. 
 
In order to study the potential of using CORM-3 as a therapeutic agent, several studies 
have reported using CORM-3 in vivo. In mice, CORM-3 prevents cardiac allograft 
rejection and protects myocardial cells and isolated rat hearts in ischemia reperfusion 
injury (Clark et al., 2003). This involves the activation of HO-1, sGC and ATP-dependent 
potassium channels. Mice treated with CORM-3 also have limited myocardial ischaemia-
reperfusion injury in vivo (Guo et al., 2004). CORM-3 also has significant vasodilatory 
properties, which are induced at concentrations of CORM-3 as low as 25 – 50 µM (Foresti 
et al., 2004). CORM-3 inhibits human platelet aggregation (Chlopicki et al., 2006). 
CORM-3 causes reduction of microglia activity in strokes and other neuroinflammatory 
diseases (Bani-Hani et al., 2006) and prevents cardiac allograft rejection in mice (Vadori 
et al., 2009). In a more recent study, Abid and co-workers have observed the mice that 
treated with CORM-3 (50 mg kg-1) once daily for three weeks mimicked the action of 
endogenous CO by inhibiting pulmonary vascular remodelling, so CORM-3 is a potential 
therapeutic treatment in pulmonary hypertension. (Abid et al., 2014). 
 
1.2.1.3 PhotoCORM-CN028-31 
PhotoCORM-CN028-31 ([Mn(CO)3(tpa-κ3N)]+) is a novel water-soluble photo-activated 
CORM that releases CO on exposure to UV irradiation at 365 nm and is stable in solution 
in the dark (Nagel et al., 2014). This compound releases CO in a precisely controlled 
manner. In addition, this PhotoCORM has manganese as the CO carrier and so is more 
biologically favourable compared to ruthenium-based CORMs. However, there are 
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several disadvantages associated with this compound, such as the potential damage to 
tissues cause by irradiation.  
 
Limited studies of this compound exist so far in the literature, but Nagel and colleagues 
have shown that the growth of Escherichia coli K-12 was inhibited by this PhotoCORM 
when cultures were exposed to UV light. However, no toxicity was observed in cultures 
kept in the dark. Pronounced inhibition of cultures growing in the presence of a non-
fermentable carbon source upon activation of the PhotoCORM in situ, together with the 
demonstration of CO binding to E. coli terminal oxidases suggested that the mechanism 
of action of PhotoCORM is related to the inhibition of respiration more than the toxicity 
exerted by the metal-coordinated backbone (Nagel et al., 2014). 
 
Additionally, other relevant PhotoCORMs were also investigated for their potential as 
novel therapeutic agents. One group of PhotoCORMs was based on monocationic 
manganese(I) tricarbonyls [Mn(CO)3(tmp)]+. These are stable in the dark and do not 
affect the viability of HT29 human colon cancer cells, but typically release 2 CO groups 
per molecule upon irradiation at around 360 nm, and in this activated form, significantly 
reduce the viability of such cells (Niesel et al., 2008). Researchers have shown that this 
PhotoCORM with a targeting peptide has the potential to target specific cancer cells 
(Pfeiffer et al., 2009). The linkage of [Mn(CO)3(tmp)]+ to silicium dioxide nanoparticles 
have the potential to deliver CORMs into solid tumours without adversely affecting CO 
release (Dordelmann et al., 2011). Another group of PhotoCORMs is based on the sodium 
salts of the water soluble tungsten carbonyl complex Na3[W(CO)5(TPPTS)] (Rimmer et 
al., 2010). These are stable in aerated media, but release approximately 1 CO upon 
irradiation; further CO is then released due to aerobic oxidation. These PhotoCORMs 
have been suggested as suitable for topical applications using UVA as an excitation 
source. More recently, a manganese-based PhotoCORM has been described that has 
therapeutic potential (Ward et al., 2012). Particular advantages of this CORM are that it 
releases 3 CO molecules from each molecule, is activated by light from an LED at 400 
nm, and is not toxic to RAW 264.7 murine macrophages before and after irradiation. 
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1.2.1.4 The future of CORM development 
The future design of CORMs and work to characterize them should pay special attention 
to understanding the mechanism of CO release from CORMs. It is desirable for CORMs 
to have high CO release ratios, so that less drug needs to be administered in order to 
achieve a therapeutic effect. In addition, future CORM design needs to focus on making 
CORMs more suitable for use as medical drugs. Currently we have water-soluble, 
bioactive CORMs such as CORM-3 and CORM-A1, but in order for CORMs to be a 
realistic therapy they must have highly attuned absorption into tissues and excretion from 
them, have higher biocompatibility and contain no potentially harmful components 
(Motterlini and Otterbein, 2010). 
 
It is also important that we gain a better understanding of how CO from CORMs or the 
CORM itself enters cells (Mann, 2012). For example, it is not known whether CORMs 
enter via specific transporters, or by passive diffusion. Furthermore, little is known about 
the fate of the CORM backbone or the released CO after it has entered cells (Mann, 2012). 
However, Raman microscopy has shown that when HT29 human colon cancer cells are 
exposed to CORM, most of the CORM localizes around the nucleolus (Meister et al., 
2010). 
 
It is also vital that future CORMs are designed with the availability of reliable, control 
(inactive) molecules in mind. Currently, despite the reported use of three different control 
molecules for CORM-3: inactive CORM-3 (iCORM-3), myoglobin inactivated CORM-
3 (miCORM-3) and RuCl2(DMSO)4, there is no control molecule for this compound for 
which the chemistry is completely understood, or that mimics the in vivo breakdown 
products of this CORM precisely. 
 
1.2.2 The therapeutic effects of CORMs 
As mentioned above, much research focuses on using CO as a therapeutic agent due to 
its beneficial effects in mammalian systems. CORMs were designed to delivery CO to 
the site where it is required in a safe and efficient way (Johnson et al., 2003, Motterlini 
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and Otterbein, 2010, Romao et al., 2012). Here I will give only a brief overview of this 
area of research. 
 
1.2.2.1 Vasoactive properties 
CORMs are considered to have great potential in regulating vasoactive processes in a 
variety of diseases (Motterlini and Otterbein, 2010). CORM-2 causes vasodilation and 
reduces hypertension in rat aorta, whereas the control molecule RuCl2(DMSO)4, which 
is structurally similar to [Ru(CO)3Cl2]2, but with the carbonyl groups replaced with 
DMSO, is unable to cause these effects, suggesting that CO, rather than the CORM 
backbone is the causative agent (Motterlini et al., 2002). Importantly, no cytotoxicity was 
experienced in vascular smooth muscle cells treated with up to 420 µM CORM-2 over 3 
h. CORM-3 also has significant vasodilatory properties, which are induced at 
concentrations of CORM-3 as low as 25 – 50 µM (Foresti et al., 2004). A major advantage 
of CORM-3 is that it has relatively low toxicity: concentrations less than 500 µM are not 
toxic to porcine aortic endothelial cells or to primate peripheral blood mononuclear cells 
in vitro (Vadori et al., 2009). Furthermore, the non-metal CORM, CORM-A1 causes 
significant but slow-acting and sustained vasodilation of precontracted aortic rings, 
thereby mimicking endogenous CO, while the inactive compound (iCORM-A1) does not. 
 
1.2.2.2 Anti-inflammatory properties 
CORMs are also considered to have great potential as anti-inflammatory agents 
(Motterlini and Otterbein, 2010). Several CORMs have been shown to decrease levels of 
anti-inflammatory intermediaries and to reduce levels of TNF-α and NO in LPS 
stimulated macrophages (Sawle et al., 2005). CO delivered by CORMs may also be 
beneficial in the treatment of inflammation associated with arthritis. CORM-3 reduced 
levels of inflammatory cytokines in joint tissues and reduced the recruitment of 
inflammatory cells, joint inflammation and degradation of cartilage in animal models of 
arthritis (Ferrandiz et al., 2008). In addition, CORM-2 has been shown to substantially 
reduce the inflammatory response induced by cytokines in human colonic epithelial cells. 
This includes reduced expression of nitric oxide synthase-2 (NOS-2) and subsequent 
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production of nitrite as well as differential-regulation of inflammatory genes involved in 
intestinal inflammation and cancer progression (Megias et al., 2007). 
 
1.2.2.3 The effects of CORMs on organ transplantation 
Much research has been undertaken into the protective potential of CO in organ transplant 
systems, and it has been found to have significantly beneficial effects (Akamatsu et al., 
2004). An early study into the biological activity of CORM-3 investigated cardiac 
allograft rejection in mice. This study showed in the presence of CORM-3, but not an 
inactive control compound, greatly increased the survival rate of transplanted hearts 
(Clark et al., 2003). CORMs have also been shown to prevent ischemia reperfusion injury 
in intestinal grafts via a sGC-dependent mechanism (Nakao et al., 2006b). The reduction 
of pro-inflammatory cytokines by CORMs is also thought to be important in increasing 
the survival rate of transplant patients (Nakao et al., 2006a). In addition, CORMs and 
saturated solutions of CO added to the organ preservation solution have been shown to 
greatly benefit the health of the transplanted organ (Sandouka et al., 2006, Musameh et 
al., 2007, Pizarro et al., 2009). The mechanisms by which CO and CORMs induce these 
effects is not fully understood, but there is evidence that sGC (Nakao et al., 2003), 
cytochrome p450 (Nakao et al., 2008) and the reduction of inflammatory cytokine levels 
(Nakao et al., 2006a) are involved. 
 
1.2.2.4 Limitations to the therapeutic use of CORMs 
Despite the many potential advantages of CORMs compared to CO gas as a therapeutic 
agent, they also have some disadvantages. For example, consideration must be given to 
the fate of the CORM backbone following the release of CO. It is important that the 
resulting compound, and any residual breakdown products are not toxic, and that they are 
not metabolised by the body to subsequently produce toxic products. CORM-2 and 
CORM-3, which have potent therapeutic effects, both contain ruthenium, which is not 
found naturally in the body and therefore they are not biological favourable. 
 
1.2.3 Antimicrobial activity of CORMs 
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In contrast to the numerous studies into the therapeutic effects of CO and CORMs, more 
limited research has done into antimicrobial activity of CORMs. A variety of CORMs 
has been used against bacteria, including CORM-2, CORM-3, CORM-A1, CORM-371, 
CORM-401 and several PhotoCORMs (Davidge et al., 2009b, Desmard et al., 2009, 
Desmard et al., 2012, McLean et al., 2013, Murray et al., 2012, Nagel et al., 2014, Nobre 
et al., 2009, Nobre et al., 2007, Rana et al., 2014, Tavares et al., 2013, Tavares et al., 
2011, Wilson et al., 2013). Here I only address the antimicrobial activity of two 
commonly studied CORMs: CORM-2 and CORM-3. Note that recent data on CORM-3 
casts doubt on the previous assumptions that CO release is a/the major cause of 
antimicrobial activity (Southam et al., 2018). 
 
1.2.3.1 The antimicrobial effects of CORM-2 
Work by Nobre and colleagues provided the first evidence about the antibacterial action 
of CORM-2. They tested the effect of CORM-2 on the growth and viability of both E. 
coli and S. aureus cells under aerobic and anaerobic conditions (Nobre et al., 2007). Their 
results showed a significant killing after exposure cell cultures to 250 M CORM-2. CO 
release was claimed to be the major cause of the bactericidal effect as CORM-2 had no 
effect in the presence of the CO scavenger haemoglobin. However, CO release was not 
detected in the media containing CORM-2. Moreover, CORM-2 was more toxic to 
aerobic E. coli cultures than anaerobic E. coli cultures in an initial 30 min exposure, but 
this trend reversed after the addition of CORM-2 (Nobre et al., 2007). 
 
Nobre and co-workers later carried out another investigation on the effect of CORM-2 on 
transcriptional regulation in E. coli cells (Nobre et al., 2009). In agreement with the 
previous finding that CORM-2 was more toxic to E. coli under anaerobic conditions, 
CORM-2 had greater effect on the transcriptome of E. coli anaerobic cultures. They also 
showed CORM-2 had effects on genes involved in methionine metabolism and biofilm 
formation of E. coli (Nobre et al., 2009). 
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Based on the confirmation that CORM-2 has bactericidal effect on E. coli cells, Tavares 
and colleagues studied the stimulation of formation of reactive oxygen species (ROS) as 
the mechanism behind its (Tavares et al., 2011). Their research appeared to show that 
ROS content was increased in E. coli cells treated with CORM-2. The generation of ROS 
in the presence of CORM-2 also resulted in damage to DNA. Importantly, CORM-2 
generated hydroxyl radicals in vitro (Tavares et al., 2011). 
 
In addition, researchers have reported on the antimicrobial action of CORM-2 on 
commensal E. coli strain, Bang and co-workers evaluated the effect of CORM-2 on 
several clinical isolates of E. coli (Bang et al., 2014). The strains used were multidrug 
resistant strains producing extended-spectrum β-lactamases (ESBLs). CORM-2 inhibited 
the growth of ESBL-producing E. coli and killed the cells within 4 h (at a concentration 
of 500 M). The bactericidal effect of CORM-2 was much greater than with 
nitrofurantoin, an antibiotic used against ESBL-producing E. coli  (Bang et al., 2014). 
This study revealed the potential application of using CORMs in the clinic for treatments 
of bacterial resistant strains. 
 
More recently, Qiu and colleagues examined the effect of CORM-2 on an E. coli sepsis 
model in mice (Qiu et al., 2015). CORM-2 suppressed bacterial vitality and toxicity by 
damaging bacterial structure. The survival rate of mice with E. coli sepsis in a dose-
dependent fashion increased after CORM-2 intervention. Meanwhile, no effect was 
observed with the CO-depleted control iCORM-2. CORM-2 also enhanced bacterial 
clearance in mouse livers, lungs, spleens and kidneys. These beneficial effects of CORM-
2 may also associated with the modulation of key genes by CORM-2 in E. coli cells. 
 
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen of animals, plants 
and humans (Bodey et al., 1983). The first examination of the bactericidal activity of 
CORM-2 against P. aeruginosa planktonic cells was by Desmard and co-workers 
(Desmard et al., 2012). A very low concentration of CORM-2 (10 M) inhibited bacterial 
growth. 100 M CORM-2 killed P. aeruginosa planktonic cells and reduced oxygen 
 27 
consumption. The bactericidal effect of CORM-2 was prevented by the presence of N-
acetyl cysteine (NAC) (Desmard et al., 2012). 
 
P. aeruginosa infections are particularly difficult to treat due to this organism’s ability to 
form biofilms, which offers protection against antimicrobials (for details see section 
1.3.1). The first investigation of the antimicrobial effect of CORM-2 against P. 
aeruginosa biofilms was by Murray and colleagues (Murray et al., 2012).  They showed 
that addition of CORM-2 prevented biofilm maturation and destroyed established 
biofilms. The combination of CORM-2 with tobramycin, an established antibiotic used 
in P. aeruginosa infections, was more effective at preventing biofilm maturation. 
Additionally, CORM-2 (50 - 200 μM) disrupted P. aeruginosa biofilm formation on 
human bronchial epithelial cells, and these concentrations are not cytotoxic to the cells. 
Importantly, Murray and colleagues concluded that the inhibitory activity of CORM-2 
observed in this study was not attributed to ROS formation, due to the detection of ROS 
even though addition of cysteine inhibited CORM activity in cells (Murray et al., 2012). 
 
The therapeutic properties of CORM-2 led Tavares and co-workers to investigate the 
effect of CORM-2 on Helicobacter. pylori, a major pathogen causing gastric ulcer 
diseases (Tavares et al., 2013). This study showed that CORM-2 effectively killed all H. 
pylori strains even those resistant to antibiotics. Control experiments with the addition of 
the control compound iCORM-2 showed no bactericidal effect, revealing that the 
bactericidal effect was attributed to CO release. In addition, the combination of antibiotic 
and sub-lethal doses of CORM-2 enhanced the ability of killing H. pylori cells. Moreover, 
in vivo studies done in human macrophages showed the ability of H. pylori to infect 
murine macrophages was inhibited by CORM-2 (Tavares et al., 2013). 
 
1.2.3.2 The antimicrobial effects of CORM-3 
The first demonstration of the antibacterial action of CORM-3 against both E. coli and S. 
aureus cells was also by Nobre and co-workers (Nobre et al., 2007). Their work revealed 
a significant decrease on the viability of E. coli and S. aureus cells after exposure cell 
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cultures to a higher concentration of CORM-3 (400 M) compared to CORM-2 (250M). 
However, aerobic S. aureus cell cultures were more resistant to CORM-3. Similarly to 
CORM-2, the antibacterial actions of CORM-3 also depended on CO release due to 
CORM-3 lost bactericidal effect in the presence of CO scavenger haemoglobin; CORM-
3 also not released CO when dissolved in the media (Nobre et al., 2007). 
 
Davidge et al. found that, even though CORM-3 was bactericidal against E. coli cells 
under both aerobic and anaerobic conditions, CORM-3 completely inhibited the aerobic 
cell cultures at lower concentrations (100 M) than required under anaerobic conditions 
(200 M). Meanwhile, after exposure of cell cultures to CORM-3 for 2h, 30 μM CORM-
3 was needed to reduce the number of viable cells 10-fold under aerobic conditions, 
whereas 100 μM CORM-3 had no effect on the cell viability under anaerobic conditions. 
Interestingly, CORM-3 but not the equivalent concentration of CO-saturated solution 
prevented bacterial growth. Ruthenium from CORM-3 was found to accumulate greater 
inside E. coli aerobic cells than in anaerobic cells, which may partly explain the higher 
toxicity of CORM-3 against aerobic cell cultures.  Furthermore, CORM-3 was shown to 
inhibit bacterial respiration accompanied by the formation of CO adducts of terminal 
oxidases. Importantly, transcription in aerobic cultures was shown to be affected more by 
CORM-3 than in anaerobic conditions. The most affected gene in the presence of CORM-
3 was spy, an envelope-stress-induced periplasmic protein. The spy gene was up-
regulated more than 100-fold anaerobically, and 26-fold aerobically (Davidge et al., 
2009a). 
 
A subsequent time-resolved transcriptional analysis compared the effects of a sub-lethal 
concentration of CORM-3 (40 μM) with the control compound (inactivated CORM-3 
(iCORM-3)) on gene expression in aerobically grown E. coli (McLean et al., 2013). In 
this study, they found the control compound evoked a much smaller transcriptomic 
response than CORM-3, with only 2% of the genome significantly affected, compared to 
23% at 40 min in the presence of CORM-3. Furthermore, both of the compounds can 
rapidly enter the cells, but iCORM-3 accumulated at much lower levels than CORM-3, 
indicating that the smaller effect of iCORM-3 may be caused by poor cellular penetration. 
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Importantly, this study also identified that one target of CORM-3 and iCORM-3 activity 
is sulphur metabolism (McLean et al., 2013). 
 
Wilson and colleagues provided another study of the effects of CORM-3 on microbial 
respiration (Wilson et al., 2013). In this study, addition of CORM-3 to cultures of E. coli 
resulted in a period of respiratory stimulation followed by inhibition, while higher 
concentrations of CORM-3 resulted in increased stimulation for a shorter time period, 
followed by more marked inhibition. It was also found that incubation of CORM-3 with 
the bacterial suspension under anoxic conditions for increased time periods resulted in 
greater inhibition. They suggested that this observation was due to CORM-3 enabling the 
movement of potassium or sodium ions into the cell, which resulted in less back pressure 
from positive charges outside of the cell, and therefore favouring proton extrusion 
coupled to respiration (Wilson et al., 2013). 
 
The potential of CORM-3 as an antimicrobial agent for treatment of P. aeruginosa related 
infections was first confirmed by significantly inhibiting the growth of an antibiotic-
resistant P. aeruginosa clinical isolates in the presence of very low concentrations (0.5 – 
10 µM). CORM-3 (10 µM) was as effective deceasing the bacterial count to the same 
extent as the antibiotic amikacine (50 mg l-1, or 0.8 mM), and more effective than another 
antibiotic ticarcilline (50 mg kg-1). Moreover, CO is known to bind to cytochrome c 
oxidase in P. aeruginosa (Parr et al., 1975); spectroscopic analysis of P. aeruginosa cells 
after exposure to CORM-3 revealed the formation of CO-adducts of terminal oxidases. 
The antimicrobial effect of CORM-3 was mediated by the inhibition of respiration, and 
probably not linked with ROS overproduction. The addition of thiol compounds cysteine, 
glutathione and the thiol donor N-acetylcysteine (NAC) prevented the effects of CORM-
3 on P. aeruginosa cell growth. Furthermore, this group investigated CORM-3 activity 
in vivo, and found that CORM-3 had a direct bactericidal effect on a model of PAO1 
bacteraemia in mice (Desmard et al., 2009). In later work by the same group, they found 
that CORM-3 exerted a significant bactericidal effect on P. aeruginosa PAO1 together 
with decreased oxygen consumption (Desmard et al., 2012). 
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1.2.4 The mechanisms behind CORM bactericidal activity 
Despite CORMs being promising antimicrobial agents, many questions about how 
CORMs kill bacteria still remain in this field. Initially, inhibition of respiration was 
considered to be a likely cause of the bactericidal properties of CORMs, and several 
pieces of evidence support this hypothesis. CO from CORM-3 has been shown to bind 
rapidly to the terminal oxidases of the aerobic respiratory chains of E. coli and P. 
aeruginosa, and a reduction in oxygen consumption in the later has been observed 
following treatment with this compound, prior to a decrease in viability. In contrast, there 
is evidence that inhibition of respiration is not the main cause of killing by CORMs. In 
C. jejuni, CORMs have been shown to inhibit respiration, without adversely effecting 
growth or viability, and transcriptomic analysis of E. coli treated with CORM-3 suggests 
that while respiratory genes are greatly affected by this compound, the expression levels 
of a wide variety of non-respiratory genes are also significantly affected. Furthermore, 
the growth and viability of anaerobic cultures is also adversely affected by treatment with 
CORM-3 and CORM-2.  An alternative hypothesis is that CORMs are bactericidal 
because they generate ROS. Again there are several pieces of evidence both for and 
against this suggestion. Research has shown that CORM-2 generates hydroxyl radicals in 
vitro, and that E. coli mutants unable to resist oxidative stress are hypersensitive to killing 
by this compound. However, other work has found no evidence of ROS formation by 
CORM-3 or CORM-2. 
 
1.3 The bacterial biofilm 
A biofilm could be simply defined as a community of microorganisms bound to a surface, 
or to each other. When a cell switches from a planktonic mode of growth to a biofilm 
mode of growth, it undergoes a phenotypic change that leads to self-aggregation and 
transition to a lifestyle different from its planktonic counterparts (Costerton et al., 1995). 
 
Biofilms are ubiquitous. In nature, biofilms can be found in freshwater systems, including 
rivers, abattoir effluents, marine environments, desert rocks and leaves (Costerton et al., 
2007). In human, a lot of human infections are involved with biofilms, such as otitis media, 
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chronic bacterial prostatitis, cystic fibrosis, and periodontitis etc. (Donlan and Costerton, 
2002). Moreover, biofilm formation can result in several medical problems, and one of 
the most common consequences is the growth of biofilms on medical devices. For 
example, biofilm growth on an implanted device can result in chronic infections such as 
conjunctivitis (van Bijsterveld and Jager, 1996), urinary tract infection (Trautner and 
Darouiche, 2004) or pelvic inflammatory disease (Pal et al., 2005). Another common 
example is biofilm growth on contact lenses which can lead to microbial keratitis 
(McLaughlin-Borlace et al., 1998). McLaughlin-Borlace et al. studied patients with 
microbial keratitis, and observed biofilms on both the surface of contact lens and contact 
lens storage cases, which caused contaminations on both lenses and lens solutions 
(McLaughlin-Borlace et al., 1998). Conversely, certain body tissues in healthy 
individuals are actually protected from extraneous organisms by biofilms. Thick biofilms 
in the intestine are viscous moving populations that occupy binding sites on endothelial 
cells that would otherwise be targets for pathogenic adhesions. In the intestine, they also 
play important roles in digestion, gut physiology and metabolism. Through a series of 
intestinal biopsies, Hartley et al were the first to discover that commensal bacteria adhere 
to the large intestine (Hartley et al., 1979). They found that E. coli was present at densities 
of 103 - 107 cells per gram of tissue. Furthermore, the effect of biofilms on industry is 
also large and wide-ranging. Examples include biofilm-related animal and plant diseases 
have detrimental effects on the farming industry, spoiling crops and lowering yields, an 
example being mastitis, which affects milk production (Melchior et al., 2006). Biofilm 
growth on water pipes is a potential problem, especially in drinking water systems (Juhna 
et al., 2007). 
 
Biofilm development and structure vary greatly due to differences in the physical and 
chemical nature of the substrates and the surrounding environment, as well as the species 
composition of the biofilm. There are four general stages in the formation of extracellular 
biofilms: reversible-irreversible attachment, microcolony formation, biofilm maturation 
and dispersal (Figure 1.2) (Kostakioti et al., 2013). The formation of an extracellular 
biofilm starts with bacterial adherence on a surface. This includes reversible and 
irreversible attachments that can be affected by some species-specific factors. Initially, 




Figure 1.2 Biofilm development. The general stages in biofilm development and the 
inhibiting and/or disrupting biofilm formation strategies at each stage (Kostakioti et al., 
2013).   
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(Beloin et al., 2008, Donlan, 2002). Cells toward or backward from the contact surface 
can be driven by medium properties (nutrients, pH, temperature) and bacterial cell surface 
components (Donlan and Costerton, 2002). If the bacteria can endure hydrodynamic 
forces and remain adhering on the surface, they can attach to the surface irreversibly. The 
next stage of biofilm development is biofilm maturation. The exopolysaccharide matrix 
(EPS) encloses the biofilm in this stage. The EPS, as the name suggests, consists of a 
highly hydrated sticky mixture of polysaccharides excreted by members of the 
community to ‘cement’ its cells to each other and to the surface. As well as providing a 
means to adhere to a surface, the EPS serves as a store of carbon substrates and water, a 
protective barrier from the effects of physical, chemical and biological challenges and a 
medium for communication and genetic exchange. EPS components are vary depending 
on the environment conditions (Harmsen et al., 2010). In the final stage of biofilm 
development, the cells may escape from the matrix that is known as the 
detachment/dispersal of cells. Besides passive dispersal factor such as shear stresses, 
environmental changes can lead bacteria to decide whether remain biofilm mode growth 
or resume a planktonic lifestyle (Kostakioti et al., 2013). 
 
Biofilm development is a complex process that requires co-operation and communication. 
Evidence for the role of quorum sensing (QS) in biofilm formation has accumulated in 
recent years. QS is a communication system existed in a bacterial community, due to the 
production of the signalling inducer compounds such as N-acyl homoserine lactone (AHL) 
and a corresponding receptor. The transcription of certain genes is activated when the 
inducer binds to the receptor. When cells are in sufficient proximity to each other, inducer 
concentration is increased, so the receptor is activated. There are several QS mechanisms 
employed by bacteria. Most Gram-negative bacteria use the LuxI/LuxR system. The 
product of luxI is responsible for the synthesis of a homoserine lactone (HSL) which, 
when accumulated in sufficient concentrations, is detected by the product of the luxR 
gene, and activates transcription of a set of target genes (Madigan, 2012). 
 
Antibiotics are the primary treatment strategic for bacterial infection. However, it was 
realized in the early 1980s, following failed antibiotic treatment in cystic fibrosis patients, 
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that growth in a biofilm increased the resistance of its residents to antibiotics (Costerton 
et al., 1981). Since then, it has been widely accepted that biofilm bacteria are less 
sensitive to antibiotics compare to their planktonic counterparts. The reason that biofilms 
are so much more resistant than planktonic cells is still not clear, but several hypotheses 
have been proposed. It may be that the penetration of the antibiotic into interior of the 
biofilm is restricted by the biofilm itself, particularly the protection from the EPS, which 
causes poor antibiotic penetration (Lewis, 2001). Another possible mechanism is the 
formation of persister cells, they are specialised antibiotic-tolerant spore-like cells 
developed in the biofilm. Even if a large proportion of susceptible cells die in the biofilm 
during antibiotic treatment, persisters will still be protected from immune attack by the 
EPS (Lewis, 2007). Other hypotheses also include nutrient limitation and slow growth, 
adaptive stress responses (Stewart, 2002). These factors are shown diagrammatically in 
Figure 1.3. It seems likely, given the wide range of growth stats that exist in a biofilm, 
that all of these factors could play a role. 
 
1.3.1 Pseudomonas aeruginosa 
P. aeruginosa is an aerobic Gram-negative bacterium. It is ubiquitous and can be easily 
identified due to its pearlescent shape and grape-like odour in vitro. Although the optimal 
metabolism of P. aeruginosa is normally aerobic respiration, it can also grow 
anaerobically while use nitrate as a terminal electron acceptor (Palmer et al., 2007). P. 
aeruginosa can in microaerobic or anaerobic environments in certain circumstances. One 
common example is P. aeruginosa colonization in the lung of cystic fibrosis patients 
where oxygen concentration is low due to the thick layer of lung mucus. 
 
1.3.1.1 P. aeruginosa biofilm formation 
P. aeruginosa is one of the model organism to study in the context of biofilms. The 
process of P. aeruginosa biofilm formation is listed in Figure 1.4 (Rasamiravaka et al., 
2015). In general, P. aeruginosa planktonic cells will first attach to a surface that is 
covered in a conditioning layer. A conditioning layer is a film of macromolecules that 




Figure 1.3 Four possible mechanisms of biofilm antibiotic tolerance. This figure is a 
cross-section of a biofilm with the attachment surface (grey) at the bottom and the 
aqueous phase containing the antibiotic (yellow) at the top. In zones where there is 
nutrient depletion (red), antibiotic action may be antagonised. Some bacteria may have 
active stress responses (green), while others may differentiate into a protected 




Figure 1.4 Biofilm lifestyle cycle of P. aeruginosa PAO1 grown in glucose minimal 
media. In stage I, planktonic bacteria initiate attachment to an abiotic surface, which 
becomes irreversible in stage II. Stage III corresponds to microcolony formation. Stage 
IV corresponds to biofilm maturation and growth of the three-dimensional community. 
Dispersion occurs in stage V and planktonic bacteria that are released from the biofilm to 
colonize other sites. The biofilm formation by P. aeruginosa PAO1 was revealed with 
Syto9 and visualized in Leica DM IRE2 inverted fluorescence microscope with 400x 
magnification at 2 h (Stage I), 8 h (Stage II), 14 h (Stage III), 1 to 4 days (Stage IV), and 
5 days (Stage V). Images represent a 250 × 250-𝜇m field (Rasamiravaka et al., 2015). 
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happens. In static environment, flagella are required for initial surface contact. Flagellar 
stators are necessary for biofilm formation in P. aeruginosa but are not required for 
swimming motility. Secondly, irreversible attachment is the next stage in P. aeruginosa 
biofilm development. This stage is the change from reversible to irreversible attachment 
that marks the transition of planktonic to biofilm physiology. One of the most significant 
components of a biofilm community is the exopolysaccharide matrix (EPS, also termed 
extracellular polysaccharide or extracellular polymeric substance). A major component 
of EPS produced by P. aeruginosa is alginate, whose biosynthesis is carried out by the 
products of the algA, C and D genes (Olvera et al., 1999). The increased production of 
alginate is positively regulated by the sigma factor σ22, which also down-regulates the 
production of flagellin (Garrett et al., 1999). Although overproduction of alginate during 
lung infection is known to enhance antibiotic resistance and pathogenesis, it is not thought 
to be essential for biofilm formation and EPS production in P. aeruginosa (Ryder et al., 
2007). This finding led to the recent discovery of two additional polysaccharides, the 
synthesis of which are encoded by the psl and pel genes. Psl, thought to be rich in 
mannose and galactose, has an important function in the P. aeruginosa biofilm EPS, 
possibly in biofilm maturation or structure differentiation, whereas Pel is glucose-rich 
and functions in pellicle production (Ryder et al., 2007). In P. aeruginosa biofilms, 
extracellular DNA has been shown to be prominent in biofilm stalks, and derived from 
genomic DNA, possibly in lysis events co-ordinated by quorum-sensing and iron 
regulation (Allesen-Holm et al., 2006). QS in P. aeruginosa occurs through two 
hierarchical systems which affect swarming (Shrout et al., 2006), DNA release (Allesen-
Holm et al., 2006) and matrix production (Sakuragi and Kolter, 2007), ultimately 
affecting biofilm development and structure, although this may not necessarily be the 
case in vivo (Schaber et al., 2007). In the final stage, P. aeruginosa cells are detaching 
from the biofilm. Co and colleagues discovered mucins, a biological gel produced by 
epithelial tissue, separate and disperse the cells in P. aeruginosa biofilms into suspension 
(Co et al., 2018). 
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1.3.1.2 Consequences of biofilm formation in P. aeruginosa infections 
P. aeruginosa is a pathogenic bacterium that causes opportunistic infections. P. 
aeruginosa can infect numerous kinds of hosts including plants, animals (Rahme et al., 
1995), nematodes (Gallagher and Manoil, 2001), fungi (Hogan and Kolter, 2002), and 
insects (Miyata et al., 2003). In humans, P. aeruginosa can result in acute pneumonia, 
bacteraemia, burn wound infections, meningitis, otitis externa, otitis media, ulcerative 
keratitis and urinary tract infections (Lyczak et al., 2000, Moore and Flaws, 2011, Sadikot 
et al., 2005) in addition to Cystic Fibrosis (CF) lung infections.  
 
The role of biofilms in the lungs of CF patients has been widely studied. Because a 
leading cause of CF-related infection is P. aeruginosa, this species is a popular candidate 
for biofilm research. CF results in the accumulation of mucus in the lungs, in which 
colonization by opportunistic bacteria can take place. Biofilm formation then occurs, and 
due to the combination of a decreased antibiotic response, a switch to a mucoid phenotype 
(alginate production), difficulty of dislodging mucus, and a host response that is more 
damaging to the host than to the biofilm, a severe chronic infection results (Parad et al., 
1999, Post et al., 2004). 
 
A large body of evidence confirmed that P. aeruginosa biofilms persist in the lungs of 
CF patients. The presence of microcolonies and large biofilm-like structures in the 
airways of CF patients was observed by microscopic examinations on sputum samples 
and lung tissue sections collected from CF patients (Worlitzsch et al., 2002). These 
bacteria within the biofilm-like structures were identified as P. aeruginosa by 
fluorescence (Bjarnsholt et al., 2009). In the study by Bjarnsholt et al. (2009), they 
suggest that without sufficient antimicrobial treatment, the existence of these biofilms 
covers the entire lung; in contrast, in patients who have aggressive antibiotic treatment, 
biofilms are limited to the conductive region, and not present in the lower airways. 
  
Numerous consequences occur in the CF lung due to the formation of P. aeruginosa 
biofilms. The persistence of P. aeruginosa may be due to several characteristics of 
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biofilms including antibiotic resistance, immune resistance and possibility of bacterial 
mutants. In addition, Wolfgang et al. (2004) have found that the spread of the 
microorganism was limited by contacting P. aeruginosa with airway fluid. Indeed, Govan 
and Deretic (1996) pointed out bacterial colonizers of the CF lung rarely have systemic 
spread. So the biofilms have shown some survival advantages because of the colonization 
of infecting bacteria. However, the precise reason that biofilms are so much more resistant 
than planktonic cells is still not clear. 
 
1.3.1.3 Current treatments for P. aeruginosa infections in CF 
Current treatments of P. aeruginosa infections of the cystic fibrosis lung include oral and 
parenteral antibiotics, and especially the inhaled nebulized antibiotics. The 
aminoglycoside antibiotic tobramycin has the most frequently used and has been most 
studied (Gibson et al., 2003, Ryan et al., 2011). The European CF society (ECFS) 
recommended inhaled aztreonam lysine or Colistimethate (2 MU twice daily) as the 
currently widely used therapy for patients with chronic P. aeruginosa (Castellani et al., 
2018). 
 
One particular efficient treatment for CF lung infections is antibiotic inhalation therapy. 
In the study by Ryan et al. (2011), the efficacy of several inhaled antibiotics including 
aztreonam lysine, ceftazidime, cephaloridine, colistin, gentamicin, taurolidine, 
tobramycin, and a gentamicin/carbenicillin combination were investigated. The 
utilization of these inhaled antibiotics can strengthen lung function and weaken the 
frequency of exacerbation when compared to a placebo. The advantages of inhalation 
therapy for P. aeruginosa infections in the CF have been highlighted for over 45 years 
(Mearns, 1970). This therapy is a highly effective way to treat lung disease especially, 
because it can maximize the dose at the location of the disease instead of systemic 
exposure and toxicity to the rest of the body. 
 
Colistin is a member of the polymyxin group. It was initially used therapeutically in the 
1950s (Kumazawa and Yagisawa, 2002) but was abandoned due to the reported high 
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incidence of nephrotoxicity in early 1980s (Brown et al., 1970). However, the emergence 
of multidrug-resistant Gram-negative bacteria and the shortage of new antimicrobial 
agents have brought back the interest of using colistin as a valuable therapeutic option. 
There is increasing research with use of aerosolized colistin in P. aeruginosa infections 
in cystic fibrosis (Jensen et al., 1987, Hodson et al., 2002, Berlana et al., 2005, Herrmann 
et al., 2010). 
 
1.3.1.4 Antimicrobial resistance 
Antimicrobial resistance (AMR) is defined as the resistance of microorganisms to an 
antimicrobial agent to which they were once sensitive (Jindal et al., 2015). The 
appearance of antibiotic resistant strains of bacteria has been reported since the first 
introduction of effective antimicrobials in the 1930s; the use of penicillin in the clinic in 
1940 was preceded by the identification of a penicillinase, an enzyme capable of 
destroying penicillin, in 1928 by the team who had led the discovery of penicillin 
(Abraham, 1940, Davies and Davies, 2010). Resistance has since hindered the long-term 
therapeutic use of antimicrobials and in recent years the lack of novel antimicrobial drugs 
and the global spread of antibiotic resistance genes (ARG) amongst clinically relevant 
bacteria has resulted in increased hospitalization and high mortality rates amongst 
patients infected with resistant microorganisms (Berendonk et al., 2015). Antimicrobial 
resistance has spread rapidly and had already emerged before the use of antimicrobials in 
the clinic. 
 
There has been a dramatic rise of pathogenic strains of both gram-positive and gram-
negative bacteria and bacteria bearing resistance to one or more antimicrobials from at 
least three different antimicrobial classes are called multidrug-resistant (MDR) bacteria 
(Bassetti and Righi, 2015). The most frequently reported gram-positive and gram-
negative MDR bacterial strains have been called the ‘ESKAPE’ pathogens and include 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacteriaceae (Boucher et al., 2009) 
(Rice, 2008). Gram-negative bacteria have shown resistance to many different types of 
antimicrobials including penicillins, cephalosporins and quinolones (Kanj and Kanafani, 
 41 
2011). In particular, the emergence of MDR Enterobacteriaceae producing extended-
spectrum beta-lactamases (ESBLs) and MDR P. aeruginosa have led to the use of wide-
spectrum antibiotics (e.g. carbapenems/fluoroquinolones) which in turn have resulted in 
the emergence of isolates of gram-negative bacteria that are resistant to all antibiotics 
currently in use, and such microorganisms are termed extreme drug-resistant (XDR) 
strains (Gupta et al., 2011, Munoz-Price et al., 2013, Kanj and Kanafani, 2011).  
 
The molecular mechanisms of resistance in bacteria have been extensively studied. 
Emergence of antibiotic-resistant strains of bacterial organisms is primarily due to 
transfer of ARGs in populations which occur through three main mechanisms including; 
horizontal gene transfer (HGT-now implicated in the movement of ARGs), proliferation 
of antibiotic resistant bacteria due to selective pressures imposed by antimicrobial 
compounds, for example biocides and finally, genetic mutation and recombination events 
in hyper-mutating bacterial strains (Berendonk et al., 2015, Baquero et al., 2008, Wright, 
2010). Perhaps one of the most problematic drug-categories of which resistance is 
widespread belongs to the β-lactam class of antibiotics, for example penicillin. Resistance 
to these drugs is afforded by the production of β-lactamases, of which 1,000 have been 
identified. HGT has played a key role in the transmission of the β-lactam class of 
antibiotics with the plasmid-encoded β-lactamase, TEM (Davies and Davies, 2010). In 
addition to HGT, random mutation in the genes encoding β-lactamase enzymes has led 
to extended-spectrum β-lactamase variants, including CTX-M which has emerged in 
large subsets of human populations across Europe and now pose a significant threat to 
human health (Livermore et al., 2007). Alternative anthropogenic reasons for bacterial 
resistance need to be considered since therapeutic use in humans accounts for less than 
half of all antibiotics produced commercially (Davies and Davies, 2010).  Not only is the 
resistance to current antimicrobials strengthened by over-prescribed antibiotic use in the 
clinic, but antibiotic resistant hotspots are now emerging in environments where high 
bacterial loads are coupled with sub-therapeutic levels of antibiotics, for example in 
agricultural facilities (Berendonk et al., 2015). Some examples of alternative uses of 
antibiotics are surprisingly unaccounted for in the emergence of resistance, these include 
i) therapeutic/prophylactic use in household pets, ii) uses as biocides in toiletries, iii) pest 
control for plants in agricultural systems, iv) growth promotion/prophylactic use in 
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animals and finally v) cloning and selection in research and industry (Davies and Davies, 
2010). Uses of antibiotics as described above create reserves of resistance in the 
environment: genetic and genomic studies of organisms isolated in water-treatment plants 
indicate an environment where bacteria are rich in r genes, usually located on 
transmissible genetic elements (Schluter et al., 2008, Szczepanowski et al., 2009). 
 
The overuse of antibiotics to treat CF lung infections has led to high levels of antibiotic 
resistance. Emerson et al. (2010) observed that the resistance of a CF lung isolate to a 
particular antibiotic is relevant to the treatment with that antibiotic. Greater resistance 
leads to longer therapies, which consequently induces more resistance (Plummer and 
Wildman, 2011). Report from the UK Cystic Fibrosis Trust Antibiotic Working Group, 
antibiotic treatment for cystic fibrosis – 3rd edition, showing resistance rates in P. 
aeruginosa infections in the CF in the UK have risen dramatically with about 40% 
resistant to 2 or more antibiotics. Therefore, novel antimicrobial agents that could replace 
or complement current therapies are needed to fight chronic infections in CF patients. 
 
1.4 Conclusions and scope of thesis 
The potential of using CORMs as novel therapeutic agents has been widely investigated 
in the past decade. The antimicrobial activities of CORMs against both gram-positive and 
gram-negative bacteria have confirmed in vitro. Furthermore, the effects of CORMs have 
also been discovered in vivo (see section 1.2). 
 
With the growing evidence showing biofilms are resistant to antibiotic treatment, and the 
serious problems resulted from multi-drug resistant strains, using CORMs to replace or 
complement current therapies for biofilm related infections is an attractive option. 
 
The work presented in this thesis therefore aims to develop and evaluate methods for the 
growth of P. aeruginosa biofilms, in order to investigate the effect of ruthenium-based 
CORMs on P. aeruginosa biofilms. Although Murray et al. studied the effect of CORM-
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2 on P. aeruginosa biofilm, they found that CORM-2 not only kills P. aeruginosa 
planktonic cells, but also attenuates biofilm maturation and established biofilms (Murray 
et al., 2012). The disadvantage of CORM-2, insoluble in water, makes the water-soluble 
carbonyl compound CORM-3 preferable as a model compound to study its antimicrobial 
activities.  
 
In addition to a study of planktonic P. aeruginosa, biofilms formed on both 96-well plate 
and the Modified Robbins Device were examined to investigate whether ruthenium-based 
CORMs are effective against P. aeruginosa biofilm (Chapter 3). As discussed in section 
1.3, biofilm is more resistant against antibiotics compare to its planktonic counterparts, 
so the hypothesis in Chapter 3 is that P. aeruginosa biofilm will be less sensitive to 
CORMs than its planktonic cells. If this hypothesis is true, the factors related to the 
resistance of P. aeruginosa biofilm against CORMs will also be examined, such as 
penetration, oxygen limitation and nutrient limitation (Chapter 3). 
 
Although CO inhalation therapy has shown some beneficial effects (see section 1.1.3), 
accumulation of CO in biological system can have toxic effects. Thus a product that 
delivers CO by a safer mechanism, (i.e. using CORMs through inhalation or aerosol) is 
promising. Therefore, the work in this thesis was extended to apply nebulized controlled 
doses of CORMs to P. aeruginosa cells. By monitoring bacterial viability and the uptake 
of CORMs, we will assess the potential of this nebulise therapy for treating P. aeruginosa 
related infections with CORMs. CORM-3 will be used as a model CORM as it is 
chemically well characterised and is water soluble, a property of benefit in the nebulizer 
treatment. Colistin, which is a widely used antibiotic in chronic P. aeruginosa infections, 
was used in order to compare the efficiency between CORM-3 and colistin. 
 
Ruthenium-based CORMs have successfully shown the antimicrobial effects on both 
Gram-positive and Gram-negative bacteria (see section 1.2.3), but such compounds still 
have limitations for use as therapeutic agents in biological system. One example is that 
CO release is not finely controlled. However, a novel CORM with photo-labile CO 
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ligands may overcame this issue. Therefore, another investigation in this thesis will be 
given to study the antibacterial activity of a novel manganese-based PhotoCORM 
([Mn(CO)3(tpa-κ3N)]+) against P. aeruginosa planktonic and biofilm cells. This 
compound is stable in the dark, and only activated upon photoexcitation. Colistin will 




Materials and Methods 
 
2.1 Bacteriological techniques 
2.1.1 Bacterial strains 
The bacterial strain used in this study was wild type Pseudomonas aeruginosa PAO1, it 




Unless stated otherwise, all reagents were purchased from Sigma Aldrich or BDH. 
Nutrient agar, tryptone and yeast extract were all purchased from Oxoid. 
 
All media were prepared with distilled-deionised water and sterilized by autoclaving at 
121 °C and 15 psi for 15 min. All solutions and antibiotics were filter-sterilized as needed 
with Millipore filters, 0.2 μm pore size. 
 
2.1.2.1 Luria-Bertani medium (LB) 
Into 1 l of distilled H2O was dissolved tryptone (10 g), yeast extract (5 g) and NaCl (10 
g). The pH was then adjusted to 7.0 with 10 M NaOH (Sambrook and Russell, 2001). 
 
2.1.2.2 Aerobic M9 medium 
For batch growth, into 990 ml of distilled H2O was dissolved Na2HPO4 (6 g), KH2PO4 (3 
g), NaCl (0.5 g), NH4Cl (1 g). To this, 10 ml of trace element solution was added. The 
pH was then brought to 7.4 and the media was autoclaved. Before use, 10 ml l-1 of 20% 
glucose and 1 ml l-1 of 1M MgSO4 were added.  
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For chemostat growth, into 990 ml of distilled H2O was dissolved Na2HPO4 (24 g), 
KH2PO4 (12 g), NaCl (1 g), NH4Cl (2 g). To this, 20 ml of trace element solution was 
added. The pH was then brought to 7.5 and the media was autoclaved. Before use, 10 ml 
l-1 of 20% glucose, 2 ml l-1 of 1M MgSO4 and 4 ml l-1 LB were added. 
 
2.1.2.3 Anaerobic M9 medium 
Into 985 ml of distilled H2O was dissolved Na2HPO4 (6 g), KH2PO4 (3 g), NaCl (0.5 g), 
NH4Cl (1 g), KNO3 (10 g). To this, 10 ml of trace element solution was added. The pH 
was then brought to 7.4 and the media was autoclaved. Before use, 10 ml l-1 of 20% 
glucose, 1 ml l-1 of 1M MgSO4 and 5 ml l-1 LB were added. 
 
2.1.2.4 Trace elements solution for M9 medium 
Into 700 ml of distilled H2O was dissolved EDTA (5 g) and the pH was adjusted to 7.4 
with 10 M NaOH before adding FeCl3.6H2O (0.5 g), ZnO (50 mg), CuCl2.2H2O (10 mg), 
H3BO3 (10 mg), ammonium molybdate (0.12 mg) and sodium selenite (17 mg). The 
volume was made up to 1 l with distilled H2O and the medium was filter-sterilised. The 
solution stored at 4 °C. 
 
2.1.2.5 SOC medium 
Into 1 l of distilled H2O was dissolved bactotryptone (20 g), yeast extract (5 g), NaCl (0.5 
g) and 10 ml of a 250 mM solution of KCl. After adjusting the pH to 7 and autoclaving, 
10 ml of 1 M MgCl2 and 20 ml of sterile 1 M glucose were added. 
 
2.1.2.6 TB medium 
Into 100 ml of distilled H2O was dissolved bactotryptone (0.8 g) and NaCl (0.5 g). The 
medium was then autoclaved. 
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2.1.2.7 TB soft agar 
To make TB soft agar, agar (0.7 g) was dissolved in TB medium (100 ml) prior to 
autoclaving. 
 
2.1.2.8 Nutrient agar (NA) 
To make NA, dried nutrient agar (28 g) was dissolved in 1 l H2O. 
 
2.1.3 Buffers and solutions 
2.1.3.1 Phosphate-buffered saline (PBS) 
Into 1 l of distilled H2O was dissolved NaCl (8 g), Na2HPO4 (1.15 g), KCl (0.2 g) and 
K2HPO4 (0.2 g). The pH was then adjusted to 7.4 before autoclaving. 
 
2.1.3.2 CO-saturated solution 
CO-saturated solution was made by bubbling M9 medium with CO gas from a cylinder 
(BOC, Guildford) in a 7 ml Bijoux bottle fitted with a Suba-Seal and gas escape needle 
at room temperature for 15 min. This generates a solution of approximately 1 mM. 
 
2.1.4 Strain storage 
2.1.4.1 P. aeruginosa 
Strains were cultured on NA plates and stored at 4 °C and, when necessary, subcultured 
onto fresh plates. Glycerol stocks were made by adding 2 ml sterile LB medium 
containing 25% (v/v) glycerol onto a lawn of bacteria grown on NA. The bacteria were 
resuspended and removed using a sterile 1 ml pipette. This slurry was dispensed into a 




Kanamycin and colistin stock solutions were prepared in H2O and stored at 4 °C. Fresh 
solutions were made for each experiment. 
 
2.1.5 Culture conditions 
2.1.5.1 Cultures for P. aeruginosa planktonic cells growth and viability studies under 
aerobic conditions 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium (10 ml) and a 5% (v/v) inoculum added to 20 ml aerobic M9 medium 
in side arm conical flasks. The cultures were kept at 37 °C and were shaken at 200 rpm. 
For growth and viability studies, CORM-2 or CORM-3 was added after the OD of the 
cultures reached ~ 50 Klett units. 
 
2.1.5.2 Cultures for P. aeruginosa planktonic cells growth studies under anaerobic 
conditions 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
anaerobic M9 medium (10 ml) and a 5% (v/v) inoculum added to 8 ml anaerobic M9 
medium in Klett-compatible 8.5 ml screw-cap tubes. The cultures were kept at 37 °C and 
were shaken at 200 rpm. For growth studies, CORM-3 was added after the OD of the 
cultures reached ~ 40 Klett units. 
 
2.1.5.3 Cultures for P. aeruginosa energy starved growth studies 
P. aeruginosa starter cultures were grown in 20 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium (200 ml) and incubated at 37 °C shaking incubator until the OD600 
of the cultures reached ~0.5. The aerobic M9 medium were removed by centrifugation 
and replaced by M9 medium that did not supply with glucose. The cultures were 
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incubated at 37 °C shaking incubator for further 2.5 h. The cultures were centrifuged one 
more time to replace the medium with PBS (200 ml). CORM-3 was added at this point 
for further analysis. 
 
2.1.5.4 Cultures for P. aeruginosa biofilm cells growth and viability studies on a 96-
well plate 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium to an OD600 of ~ 0.05. A 200 μl aliquot of the cell suspension was 
added to each well on a 96-well plate. The plate was incubated in a non-shaking 37°C 
incubator for 48 h before the crystal violet assay (see 2.2.2) was carried out. For biofilm 
formation studies, CORM-3 was added to cell cultures before incubation. For established 
biofilm studies, CORM-3 was added after replacing planktonic cells with fresh aerobic 
M9 medium after biofilm formed for 48 h. 
 
2.1.5.5 Cultures for P. aeruginosa biofilm cells growth and viability studies on a 
Modified Robbins Device (MRD) 
The Modified Robbins Device was constructed in the engineering workshops in the 
University of Sheffield (Figure 2.1). The device was produced based on (Nickel et al., 
1985). The MRD contains twenty-five evenly spaced sampling ports on a 60 cm acrylic 
block. The removable sampling plugs were attached to each sampling port. The cell 
cultures could flow through the inner surface of the device without hampering flow 
characteristics. The biofilms are generated on the surface of each sampling plug. 
 
The MRD was connected to two 1 l reservoirs (Figure 2.2). One reservoir contains 
bacterial cell cultures held in a 45 °C water bath. The increased the temperature 45 °C 
has taken the heat loss into consideration. Another reservoir contains CORM-3 held at 
room temperature. Cell cultures were pumped from the reservoir through the MRD by a 
pump with a delivery rate set at 30 ml h-1. The sampling plugs on the MRD could then be 




Figure 2.1 The structure of the Modified Robbins Device. Apparatus designed and 
manufactured by Mark Lister, the University of Sheffield. MRD was produced based 
from Nickel’s paper in 1985 (Nickel et al., 1985). The MRD contains twenty-five evenly 
spaced sampling ports on a 60 cm acrylic block as shown in the figure above. The 
removable sampling plugs were attached to each sampling port. The cell cultures could 
flow through the inner surface of the device without hampering flow characteristics. The 









Figure 2.2 The biofilm formation on the Modified Robbins Device. The cell culture 
was grown in the bacteria reservoir in a 45 °C water bath. A pump was used to deliver 
the cell culture from bacteria reservoir to MRD. After biofilms generated on the sampling 
plugs on the MRD, CORM-3 solution was pumped from a CORM-3 reservoir to the MRD 










entire experimental apparatus was sterilized by wiping ethanol throughout the whole 
device. 
 
2.1.5.6 Cultivation of P. aeruginosa planktonic cells in batch culture 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium (10 ml) and a 4% (v/v) inoculum added to 125 ml aerobic M9 
medium in a chemostat vessel. To maintain a culture temperature of 37 °C, a water jacket 
was constructed from silicon tubing (attached to the outside of a plastic 250 ml beaker 
within which the chemostat vessel was a snug fit). This tubing was connected to a 
circulating water bath set at 45 °C (which allowed for loss of heat). Cultures were aerated 
by employing a vortex (Pirt, 1975), aided by the three baffles of the spinner flasks. To 
this end, the flask was placed on KMO 2 Basic, IKA®-Werke stirrers (SLS, arbitrary 
setting of 300), which gave stirring without splashing. 
 
2.1.5.7 Cultivation of P. aeruginosa biofilm cells in continuous culture 
Biofilms were generated on the MRD from one custom-built chemostat. The apparatus 
design is based on a Proculture Dynalift spinner flask (Sigma) with 125 ml capacity, 
which has been modified to include an overflow weir as an outlet for waste and spent 
media (Figure 2.3). Silicon tubing was connected to the overflow weir to allow waste run 
into the MRD. One hole was drilled into the plastic screw lid of the flask in which a 17 
mm subaseal (Fisher) was fitted. A silicon tube attached to a Hepa-Vent filter (Whatman) 
was pushed through the seal, which allowed gas transfer. 
 
Cultures were fed with aerobic M9 medium (see section 2.1.2.2), where glucose was the 
growth-limiting nutrient. This was pumped from a reservoir (3 l conical flask, containing 
M9 medium) using a Minipuls 2 peristaltic pump (Gilson). Glass tubing was fed through 
a silicon rubber bung in the neck of the reservoir and attached to silicon tubing. The tubing 
connected, via a flow-back trap, into the vessel’s sidearm through glass tubing inserted 




Figure 2.3 Modifications made to a Sigma Proculture Dynalift spinner flask for use 
as a chemostat vessel.  
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inserted into the bung in the neck of the reservoir to allow sterile gas exchange. The 
Minipuls 2 pump was calibrated by timing the transfer of water from a flask to a 
measuring cylinder. 
 
Growth conditions in the chemostat were kept constant. To maintain a culture temperature 
of 37 °C, a water jacket was constructed from silicon tubing (attached to the outside of a 
plastic 250 ml beaker within which the chemostat vessel was a snug fit). This tubing was 
connected to a circulating water bath set at 45 °C (which allowed for loss of heat). 
Cultures were aerated by employing a vortex (Pirt, 1975), aided by the three baffles of 
the spinner flasks. To this end, the flask was placed on KMO 2 Basic, IKA®-Werke 
stirrers (SLS, arbitrary setting of 300), which gave stirring without splashing. 
 
The whole system was sterilised in one complete piece in an autoclave at 121 °C and 15 
p.s.i. for 15 min. After autoclaving, the pump was turned on and the chemostat vessel 
allowed to fill to maximum volume with the magnetic stirrer switched on. When full, the 
pump was stopped and, once the water bath had heated the medium to 37 °C, the medium 
in the vessel was inoculated with a starter culture (1% of the chemostat volume) through 
the appropriate subaseal. The cultures were allowed to grow in batch conditions for 30 h 
with a stir rate of 100. After this time, the stir rate was increased to 260 and the medium 
flow was started at 30 ml h-1. After a further 72 h, aerobically grown biofilm-associated 
cells were harvested on the MRD and ready for analysis. A 2 ml sample was also taken 
at the entrance or the end of the MRD to test the OD600, pH and glucose limitation. To 
check for glucose limitation, culture supernatants were subjected to a glucose assay (see 
section 2.2.3).  
 
2.1.5.8 Applying CORM-3 and colistin to P. aeruginosa cells by an aerosol method 
Applying CORM-3 and colistin to P. aeruginosa was achieved by a custom-built aerosol 
system (Figure 2.4). An airway plastic tube attached to the nebuliser device (Figure 2.5) 
was connected to a pipeline that contains ten evenly spaced sampling ports. Silicon tubing 








Figure 2.5 The structure of the nebuliser device.  
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Two holes were drilled into the silicon rubber bung in the neck of the waste bottle. In one, 
a silicon tube was connected to a vacuum, which pull the gas towards the waste bottle. 
The other hole was used as gas exchange port. 
 
The nebuliser device was set up as follows nebulisation volume = 9, air-flow volume = 9 
(according to machine manufacture guideline), vacuum level was been turned on before 
inserting cells to the sampling ports. The plugs contain cells which been inserted to this 
apparatus were either from a uniform plate or the MRD. 
 
For agar plate cells studies, twelve agar plate cell circles were taken with a 4 mm borer 
from a uniform plate. Ten of these circles were inserted into the sampling ports; the other 
two were suspended in 1 ml PBS for viability assays. CORM-3 solution or colistin 
solution was sprayed onto the agar plate cells for 10 min, and then agar plate cells were 
removed from the sampling ports to the Eppendorf tubes that contain 1 ml PBS for 
viability assay. 
 
For biofilm cells studies, P. aeruginosa biofilm cells were formed on the MRD sampling 
plugs before being moved to the nebuliser apparatus. CORM-3 solution or colistin 
solution was sprayed onto these plugs for 10 min, and then biofilm cells were suspended 
in 10 ml PBS for viability assays. 
 
2.1.5.9 Cultures for growth studies of P. aeruginosa planktonic cells with 
PhotoCORM 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in M9 
medium (10 ml) and a 3% (v/v) inoculum added to 2.5 ml M9 medium in bijou bottles. 
The cultures were stressed with PhotoCORM (100-500 μM), and then irradiated for 6 min 
at 365 nm to release CO.  The cultures were grown aerobically at 37 °C for 24 h. For CO-
saturated solution experiments, the starter cells were resuspended in M9 medium to an 
OD600 of ~ 0.05. A portion (200 μl) of the cell suspension was added to each well of a 96-
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well plate and incubated on a shaking plate reader for 24 h at 37 °C. PhotoCORM (300 
μM) or CO-saturated solution (900 μM) were added after the OD595 of the cultures 
reached ~ 0.5. 
 
2.1.5.10 Cultures for growth and viability studies of P. aeruginosa biofilm cells with 
PhotoCORM 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium to an OD600 of ~ 0.05. A 200 μl aliquot of the cell suspension was 
added to each well on a 96-well plate. The plate was incubated at non-shaking 37°C 
incubator for 48 h before crystal violet assay was carried out. 
 
For biofilm formation studies, the cultures were stressed with PhotoCORM (200-500 
μM), colistin (4-8 μg/ml), CO-saturated solution (1 mM) or H2O2 (16-64 mM), and 
irradiated for 2 min at 365 nm before inoculation into wells of a 96-well plate. The plate 
was incubated in a 37 °C non-shaking incubator for 48 h. Under these conditions, a 
biofilm formed at the bottom of the well. Afterwards, both crystal violet assays and 
viability assays were carried out. 
 
For established biofilm studies, fresh M9 medium or PBS containing PhotoCORM (200-
500 μM), colistin (4-8 μg/ml), CO-saturated solution (1 mM) or H2O2 (16-64 mM) was 
added to the plate after 24 h pre-incubation, and then the plate was irradiated for 2 min at 
365 nm and incubated in a 37 °C non-shaking incubator for a further 24 h. Afterwards, 
both crystal violet assays and viability assays were carried out. 
  
2.1.6 Culture turbidity measurements 
A Klett-Summerson photoelectric colorimeter (Klett Manufacturing Co., New York) with 
a number 66 (red) filter was used to measure the growth of a culture. Before 
measurements were taken, a blank containing the sterile medium was used to zero the 
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instrument. The cultures were grown in 250 ml side-arm flasks that allowed the optical 
density reading to be taken without removing any culture from the flask. 
 
2.1.7 Viability assay 
Viability in biofilms formed either on the 96-well plate or the MRD were determined by 
suspending the cells in PBS. Under sterile conditions, cultures were serial diluted (10-5 - 
10-8) and plated onto nutrient agar plates. The plates were incubated overnight at 37 °C 
to allow the cfu ml-1 (colony forming units) to be calculated. 
 
2.1.8 P. aeruginosa uniform plate 
To make a uniform plate, 1 ml LB medium was gently mixed with 1.5 ml TB soft agar in 
sterile tube, this mixture was been kept in 50-55 °C water bath. 50 μl of P. aeruginosa 
cells from a starter culture was then properly mixed with this super-soft agar. The mixture 
was poured onto a nutrient agar plate. The top agar was solid after a few minutes. The 
plate was kept in a 37 °C incubator for 6 h. 
 
2.2 Biochemical techniques 
2.2.1 Preparation of CORM stock solutions 
2.2.1.1 CORM-2 
CORM-2 ([Ru(CO)3Cl2]2) was purchased from Sigma Aldrich. Fresh stock solutions (10 
mM or 50 mM) were made by dissolving in DMSO and wrapped in foil to exclude light. 
 
2.2.1.2 CORM-3 
CORM-3 ([Ru(CO)3Cl(glycinate)]) was obtained from Professor Brian Mann (Chemistry 
Department, University of Sheffield). This compound was synthesised by the published 
method (Johnson et al., 2007). Stock solutions were freshly made by dissolving the 




PhotoCORM-CN028-31 ([Mn(CO)3(tpa-κ3N)]+) was provided by Christoph Nagel 
(Institut fur Anorganische Chemie, Julius-Maximilians-Universitat Wurzburg, Germany) 
after synthesis following the published method (Nagel et al., 2014). A stock solution (2 
mM) was made by dissolving in water and wrapped in foil to exclude light. Stocks were 
used fresh or on the following day after overnight storage at 4 °C. 
 
2.2.2 Crystal violet assay (CV) 
After biofilm formation in a 96-well plate, the planktonic culture inside each well was 
removed by gently pipetting out. A 200 μl aliquot of 1% (w/v) crystal violet was added 
to each well and kept at room temperature for 1 min. Unbound crystal violet and any 
remaining planktonic cells were removed by inverting the plate, draining it briefly and 
then each well was gently washed with PBS for several times. Biofilm-bound crystal 
violet was eluted into the wells by adding 200 μl of a solution containing 80% ethanol 
and 20% acetone. Crystal violet was quantified using the plate reader by measuring 
absorbance at 595 nm for P. aeruginosa studies. 
 
2.2.3 Glucose assay 
Glucose was detected using the glucose oxidase (GO) Assay Kit (Sigma Aldrich) 
according to the manufacturer’s instruction. A set of solutions was prepared by mixing 
glucose standard (0-0.08 ml) with water (1-0.92 ml) in marked tubes. The reaction was 
started by adding 2 ml of Assay Reagent to each tube and proper mixed for 30 to 60 s. 
Each tube was then kept at 37 °C water bath for exactly 30 min. 2 ml of 12 N H2SO4 was 
added to each tube and gently mixed to stop the reaction. The absorbance at 540 nm was 
read for each tube. A standard curve was calculated by plotting absorbance at 540 nm (y 
axis) vs. mg of glucose (x axis) (Figure 2.6). For sample assays, glucose concentrations 




Figure 2.6 Glucose standard curves.  
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2.2.4 Determination of Minimal Inhibitory Concentration (MIC) and Minimal 
Bactericidal Concentration (MBC) 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium to an OD600 of ~ 0.05. Aliquots of 1.2 ml cell cultures were 
distributed in the marked tubes. Colistin (0.25-128 μg/ml) was added with increasing 
doubling concentrations. After aerobic incubation for 24 h, at 37 °C and 200 rpm, MIC 
was determined by reading the OD600. For the MBC determination, 10 μl of each culture 
was plated on nutrient agar plates and incubated for a further 72 h. The lowest 
concentration that prevented formation of colonies was considered as the MBC. 
 
2.2.5 Determination of Fractional Inhibition Concentration (FIC) 
P. aeruginosa starter cultures were grown in 10 ml LB broth overnight and then the LB 
removed by centrifugation at 5500 rpm for 5 min. The cells were then resuspended in 
aerobic M9 medium to an OD600 of ~ 0.05. Aliquots of 200 μl cell cultures were 
distributed in a 96-well plate. A set of solutions was prepared by combining colistin (0-8 
μg ml-1) with CORMs (0-240 μm). The solutions were added to the cell cultures on the 
96-well plate for 24 h incubation, at 37 °C and 200 rpm. MIC of colistin alone, MIC of 
CORM alone, MIC of colistin in combination and MIC of CORM in combination were 
determined by reading the OD595. The summation of FIC was calculated as the summation 
of  (MIC of colistin in combination / MIC of colistin alone) and (MIC of CORM in 
combination / MIC of CORM alone) (Punam, 2007): 
𝐹𝐼𝐶 𝑓𝑜𝑟 𝐶𝑂𝑅𝑀 =  
𝑀𝐼𝐶 𝑜𝑓 𝐶𝑂𝑅𝑀 𝑖𝑛 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛
𝑀𝐼𝐶 𝑜𝑓 𝐶𝑂𝑅𝑀 𝑎𝑙𝑜𝑛𝑒
 
𝐹𝐼𝐶 𝑓𝑜𝑟 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 =  
𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑖𝑛 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛
𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑎𝑙𝑜𝑛𝑒
 
∑ 𝐹𝐼𝐶 = 𝐹𝐼𝐶 𝑓𝑜𝑟 𝐶𝑂𝑅𝑀 + 𝐹𝐼𝐶 𝑓𝑜𝑟 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 
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The interpretation is synergy if the summation of FIC is ≤ 0.5, the interpretation is 
indifference if the summation of FIC is >0.5 and ≤4, and the interpretation is antagonism 
if the summation of FIC is >4. 
 
2.2.6 Penetration assay 
Penetration assay was conducted by modifying the protocol from Kumon et al (1994) 
(Figure 2.7). The sodium alginate (Sigma) was suspended in distilled water, then 200 μl 
of this alginate solution was mixed with 40 μl 0.1 M CaCl2 to form an alginate gel layer 
on a membrane filter in a culture plate insert (Millicell®-PCF, 0.4 μm, 12 mm in diameter, 
Millipore). After the gel had set, the insert was held in a fixed position slightly submerged 
in 15 ml water in a small beaker. A stir bar was placed at the bottom of the beaker to stir 
the water on a magnetic-stirrer device. A volume of 50 μl of CORM-3 was added to the 
gel and incubation was done at room temperature for 24 h, after which ruthenium 
concentration in the water was measured. 
 
2.2.7 Inductively-coupled plasma-mass spectrometer (ICP-MS) 
Planktonic and biofilm culture of P. aeruginosa were analysed by ICP-MS to assess the 
abundance of biologically-significant elements. In general, cell cultures treated with 
CORM-3 were centrifuged at 5500 rpm for 20 min at 4 °C. The pellets were then 
resuspended in 0.5% nitric acid and centrifuged at 13,000 rpm for 5 min at 4°C. This 
pellet wash process was repeated three times. The resulting pellets after washes were 
digested with 1 ml nitric acid (Aristar, 69% v/v) for 60 min and then diluted to 5 ml with 
1% nitric acid. Analysis of ruthenium (mass 101) was done using an Agilent 7500CE 
ICP-MS instrument using rhodium (mass 103) as an internal standard. Calibration 
standards were made up in 20% nitric acid to match the samples a sample blank was 
prepared comprising 1 ml nitric acid diluted to 5 ml with 1% nitric acid (Davidge et al., 
2009b). This ICP-MS work was all done at the Centre for Analytical Sciences (CAS, 












3.1.1 P. aeruginosa biofilm 
P. aeruginosa is an opportunistic Gram-negative pathogen of animals and plants (Bodey 
et al., 1983). It has always served as a model organism for biofilm research (Monds and 
O'Toole, 2009). The clinical interests are widely expressed in therapies that disrupt or 
prevent P. aeruginosa biofilm formation since this pathogen is an important cause of 
pulmonary disease especially in the context of cystic fibrosis (CF) (Waters and Ratjen, 
2015). 
 
Current treatments for CF include oral and parenteral antibiotics, particularly inhaled 
nebulized antibiotics (Hassett et al., 2010). With the increase in antibiotic-resistant 
bacteria, it is essential to investigate other bactericidal compounds such as CORMs to 
replace or complement current therapies to fight chronic infections in CF patients. The 
reason this resistant to therapeutic agents is the high ability of form biofilm. 
 
The reason that biofilms are so much more resistant to antimicrobial agents than 
planktonic cells is still not clear, but several hypothesises have been proposed. It may be 
that penetration of the drug into the biofilm is restricted by the biofilm itself, particularly 
the extracellular polymeric substance (EPS) component. This hypothesis was supported 
by Lewis’ group, who have shown that diffusion of a molecule through a bacterial 
aggregate results in a concentration gradient, and cells might be able to degrade or modify 
antibiotic molecules at these low concentrations before they became inhibitory (Lewis, 
2001). There are several other factors that may contribute to resistance, such as nutrient 
limitation (Anderl et al., 2003), oxygen limitation (Borriello et al., 2004), low metabolic 
 66 
activity (Walters et al., 2003), adaptive stress responses (Marr et al., 2007), and the 
formation of persister cells (Lewis, 2007). 
 
3.1.2 The antimicrobial effect of CORMs on P. aeruginosa 
The therapeutic properties of CORMs led researchers to investigate their effect on P. 
aeruginosa in the past two decades. Desmard and co-workers (2009) have shown that 
CORM-3 was bactericidal to both a laboratory strain (PAO1) and three clinical isolates 
of P. aeruginosa. Very low concentrations (0.5 – 10 µM) of the compound were needed 
to inhibit the growth of an antibiotic-resistant strain of P. aeruginosa in vitro, and these 
concentrations were 50-fold lower than concentrations that can cause cytotoxicity to 
mammalian cells (Desmard et al., 2009). Moreover, CORM-3 (10 µM) was as effective 
at reducing the bacterial count in vitro as the established antibiotics amikacine (50 mg l-
1, or 0.8 mM) and ticarcilline (50 mg kg-1). 
 
The same group found that CORM induced bactericidal effects and inhibition of P. 
aeruginosa respiration that might be due to the specific metal carbonyl used. Although 
bacterial oxygen consumption was similarly affected, ruthenium-based CORM-2 and 
CORM-3 were more bactericidal than a novel, slow CO-releaser, manganese-based 
CORM-371. CORM-A1, which does not contain a metal centre, but releases CO at a 
similar rate to CORM-371, was found to elicit only a bacteriostatic effect and mild 
perturbations in the respiratory capacity of P. aeruginosa. The abolishment of CORM 
function by NAC was also compound-dependent with the activity of ruthenium-based 
CORMs being the most affected (Desmard et al., 2012). 
 
Murray and colleagues were the first to evaluate the effects of CORM-2 on P. aeruginosa 
biofilm maturation and surface colonization. They have shown that CORM-2 (25 - 200 
μM) prevented biofilm maturation as early as 60 min after addition. CORM-2 (100 μM) 
also decreased the number of viable bacteria recovered from the biofilm as early as 30 
min after treatment, and persisting for a further 6 h. CORM-2 prevented biofilm 
maturation to a similar extent as tobramycin, an established antibiotic to P. aeruginosa 
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infections, and was more effective when combined with the drug. Additionally, CORM-
2 (50 - 200 μM) disrupted P. aeruginosa surface colonization of human bronchial 
epithelial cells, and these concentrations are not cytotoxic to the cells (Murray et al., 
2012). 
 
3.1.3 The aim of this work 
The work described in this chapter aims to compare the effects of ruthenium-based 
CORMs, CORM-2 and CORM-3, on P. aeruginosa planktonic cells with biofilm cells. It 
was hypothesised that P. aeruginosa planktonic cells would be more sensitive to 
ruthenium-based CORMs than biofilm cells. Furthermore, the mechanisms behind the 




3.2.1 The growth of P. aeruginosa planktonic cells in vitro 
Initially, the growth of P. aeruginosa planktonic cells was assessed in aerobic M9 
medium (Figure 3.1). It was found that the bacterial cells reached stationary phase after 
9 h and the doubling time was 1.7 h. 
 
In order to enhance the growth of P. aeruginosa planktonic cells, two experiments were 
conducted in this study. One culture had additional 0.4 % LB broth added to the M9 
medium (Figure 3.2A); the other experiment involved using three different concentrations 
of glucose (Figure 3.2B). The LB broth did provide more cell growth in logarithmic 
phase. Increasing glucose concentration in the medium increased P. aeruginosa cell 
growth when the culture reached stationary phase. 
 
3.2.2 The effect of CORM-3 on P. aeruginosa cells in vitro 
3.2.2.1 The effect of CORM-3 on P. aeruginosa planktonic cell growth and viability 
In order to investigate the antimicrobial action of CORM-3, its effect on the growth of P. 
aeruginosa planktonic cells was examined on 20 ml cultures growing in M9 medium. 
Cultures were grown aerobically at 37 °C until 60 Klett units was reached; cultures were 
then stressed with CORM-3 (10-100 μM). CORM-3 inhibited bacterial growth in a 
concentration-dependent manner (Figure 3.3A). CORM-3 had a slight deleterious effect 
on growth at 10 μM, with the negative impact on growth increasing as CORM-3 
concentration was increased. Meanwhile, comparing the cell growth of P. aeruginosa 
planktonic cells in the presence of CO-saturated solution (1 mM) or CORM-3 (1 mM) 
(Figure 3.3B), no effect of CO gas in solution on growth was observed in cells suggesting 
that the effect on growth by CORM-3 can be attributed to the compound as a whole and 




Figure 3.1 The growth of P. aeruginosa planktonic cells in M9 medium. P. aeruginosa 
planktonic cells were grown aerobically in M9 medium in side-arm flasks, and the optical 
densities were recorded at regular intervals by a Klett-Summerson photoelectric 
colorimeter. Values shown are the mean of at least 3 biological repeats. Error bars show 







Figure 3.2 The growth of P. aeruginosa planktonic cells in different M9 medium. P. 
aeruginosa planktonic cells were grown aerobically in M9 medium supplied with 0.4 % 
LB broth (A) or M9 medium with enhanced glucose (B) over 25 h in a plate reader under 
37 °C shaking condition. The OD595 was recorded at regular intervals. Values shown are 







Figure 3.3 The effect of CORM-3 or CO-saturated solution on the growth of P. 
aeruginosa planktonic cells. (A) The growth of P. aeruginosa was followed until a Klett 
OD of ~60 Klett was reached. The cultures were then stressed with CORM-3 (10 - 100 
μM) for 24 h. The optical density was recorded over the time course. Values shown are 
mean of at least 3 repeats. Error bars show ± S.D. (B) Cell cultures of P. aeruginosa in 
the presence and absence of CORM-3 (1 mM) or CO gas-saturated solution (1 mM) were 
added to a 96-well plastic plate. The plate was incubated for 24 h and readings were taken 
at regular intervals. Data shows the mean and standard deviation from 5 technical repeats.  
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In addition, the effect of CORM-3 on P. aeruginosa planktonic cell viability was 
investigated. Cells were grown aerobically at 37 °C for 6 h. Then CORM-3 (30 μM) was 
added to the culture. Cell viabilities were measured every half an hour till 2.5 h later 
(Figure 3.5). CORM-3 (30 μM) completely killed P. aeruginosa planktonic cell as early 
as 30 min, confirmed after 2.5 h. 
 
To find a time period in which CORM-3 can completely kill P. aeruginosa planktonic 
cells, the effect of various concentrations of CORM-3 (30 - 100 μM) was tested. Cells 
were grown aerobically at 37 °C until 30 Klett units was reached; cultures were then 
stressed with various concentrations of CORM-3 (30 - 100 μM) for 8 h. Cell viabilities 
were measured at 6 h and 8 h time points (Figure 3.6). 30 μM CORM-3 almost inhibited 
P. aeruginosa planktonic cells growth between 6 and 8 h, which then started to slowly 
recover (Figure 3.6). Increasing CORM-3 concentration to 100 μM completely killed P. 
aeruginosa planktonic cells after 8 h. 
 
3.2.2.2 The effect of CORM-3 on P. aeruginosa biofilm formation 
After the initial examination of CORM-3 on P. aeruginosa planktonic cells, it was 
important to investigate whether CORM-3 can impact the growth and cell viability of 
surface-associated P. aeruginosa biofilm cells. The biofilm cells were formed on the 
inside of a 96-well plate well (Cowan and Fletcher, 1987). In this study, to determine the 
effect of CORM-3 on P. aeruginosa biofilm formation, a 6 h-old pre-matured P. 
aeruginosa biofilm preformed on a 96-well plate, then exposure to CORM-3 (10 - 100 
μM) for further 24 h. The biomass was quantified by recording the absorbance of biofilm-
bound crystal violet (Figure 3.7). CORM-3 had a significant effect on biofilm formation 
at 10 μM with only 50% of biomass detected after CORM-3 treatment. Crystal violet 
biomass staining decreased after CORM-3 exposure in a concentration-dependent 
manner. Thus CORM-3 directly killed P. aeruginosa planktonic cells and reduced their 




Figure 3.4 The effect of CORM-3 on P. aeruginosa planktonic cell viability. P. 
aeruginosa planktonic cell cultures were grown in aerobic M9 medium for 6 h. The 
cultures were then stressed with CORM-3 (30 μM) for 2.5 h. The number of viable cells 




Figure 3.5 The effect of various concentrations of CORM-3 on P. aeruginosa 
planktonic cell viability. P. aeruginosa planktonic cell cultures were grown in aerobic 
M9 medium until a Klett OD of ~30 was reached. The cultures were then stressed with 
various concentrations of CORM-3 (30 - 100 μM) for 8 h. The number of viable cells was 
measured at 6 h and 8 h. Data shows the means and standard deviations from 2 biological 




Figure 3.6 The effect of CORM-3 on P. aeruginosa biofilm formation. A 6 h P. 
aeruginosa biofilm was formed on a 96-well plate. The biofilm was then stressed with 
CORM-3 (30 - 100 μM) for 2.5 h. Crystal violet (CV) biomass staining decreased after 
CORM-3 exposure in a dose-dependent manner. Each condition was done in triplicate. 
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3.2.2.3 The effect of CORM-3 on P. aeruginosa established biofilms 
With the purpose of examining P. aeruginosa biofilms, a Modified Robbins Device 
(MRD) was constructed and used in this study. This device allows the attachment of cells 
to twenty-five removable plug surfaces before beginning a flow of medium over those 
surfaces (see Figure 2.1 in section 2.1.5.5). The colonization of adherent bacteria cells 
was generated on the MRD for 4 h and 24 h before the number of viable sessile bacteria 
in the biofilm was evaluated by measuring the colony-forming units per cm2 (Figure 3.7). 
Thus, the biofilm cells could be easily harvested from the MRD. 
 
The effect of sonication on release of cells and biofilms from the removable plugs was 
assessed. Test biofilms were prepared, washed and vortexed in PBS, and sonicated for 90 
s. The optical densities of the resulting suspensions were measured at 600 nm, and the 
cell viabilities were recorded upon sonication (Figure 3.8). The effect of sonication on 
cell release was slight, with most cells being released after 20 s. The optical density of 
the suspension declined by 27 % with further sonication after 90 s. This is reflected by 
the viability assay data, in which the number of viable cells was reduced after 90 s. Thus, 
prolonged sonication probably causes not only release of cells but also their lysis. 
 
The bactericidal effect of CORM-3 on established biofilm that formed on the MRD was 
examined by allowing 30 μM CORM-3 solution to flow through the MRD for 2.5 h. The 
treated removable plugs were sterilized with IMS before suspended in 10 ml PBS. After 
vortexing the suspension and 20 s sonication, the number of viable sessile bacteria in the 
biofilm was evaluated by measuring the colony-forming units per cm2 (Figure 3.9). A 




Figure 3.7 The formation of P. aeruginosa biofilms on the MRD. P. aeruginosa cell 
cultures were grown in a reservoir that contained aerobic M9 medium and then pumped 
through the MRD. During the formation of P. aeruginosa biofilm on the MRD, two plugs 
were taken for viability assay at 4 h (left panel) and 24 h (right panel). The bars represent 
the average of the number of colonies from two different plugs at each time point. Error 







Figure 3.8 Sonication of P. aeruginosa established biofilms. A 24 h P. aeruginosa 
biofilm was first formed on the MRD. The biofilm cells were sonicated over the time 




Figure 3.9 The effect of CORM-3 on P. aeruginosa established biofilms. A 24 h P. 
aeruginosa biofilm was first formed on the MRD. CORM-3 (30 μM) was then pumped 
through the MRD for 2.5 h. After 20 s sonication, the number of viable sessile bacteria in 
the biofilm was counted as the colony-forming units per cm2. The bars represent the 
average of the number of colonies from four different plugs at each time point. Error bars 
show ± S.D.  
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3.2.3 The effect of CORM-2 on P. aeruginosa cells in vitro 
3.2.3.1 The MIC and MBC of colistin for the P. aeruginosa planktonic cells 
Colistin is currently widely used as an antibiotic to treat P. aeruginosa infections. The 
toxicity of colistin towards P. aeruginosa PAO1 was investigated (see section 2.2.6). This 
strain showed susceptibility to colistin with an MIC of 4 μg ml-1. Moreover, colistin acted 
as a bactericidal agent when it reached 8 μg ml-1. 
 
3.2.3.2 The effect of CORM-2 on P. aeruginosa planktonic cell growth 
To determine the susceptibility of P. aeruginosa to CORM-2 and colistin, cells cultured 
in LB overnight were used to inoculate 20 ml M9 medium in 250 ml side-arm flasks for 
measurements of optical density with a Klett meter during shaking at 200 rpm and 37 °C. 
CORM-2 (5 - 100 μM) and colistin (1 - 4 μg ml-1) were added directly to growing cultures 
in log phase, determined by a Klett OD of ~50. The cell growth was recorded by 
measuring Klett OD every 2 h for up to 24 h. It is clear that CORM-2 and colistin inhibited 
bacterial growth in a concentration-dependent manner (Figure 3.10). Addition of 5 μM 
CORM-2 slowed growth but higher concentrations (30 μM) were required to inhibit 
growth completely. Colistin (1 μg ml-1) had a slight deleterious effect on growth, with the 
negative impact on growth increasing as the colistin concentration was increased.  
 
3.2.3.3 The effect of combined CORM-2 and colistin treatment on P. aeruginosa 
planktonic cell growth 
To determine if CORM-2 would work as an adjuvant to the currently available antibiotic 
colistin, the effect of a combination of both CORM-2 and colistin on the growth of the P. 
aeruginosa planktonic cells in vitro was examined. The experiment was carried out on 20 
ml cultures grown in M9 medium. Cultures were grown aerobically at 37 °C until 50 Klett 
units were reached and then were stressed by the addition of 2 μg ml-1 colistin combined 
with a sub-lethal dose of CORM-2 (Figure 3.11). The combination of CORM-2 and 
colistin significantly inhibited cell growth during log phase, however, the cell recovery 







Figure 3.10 The effect of CORM-2 or colistin on P. aeruginosa planktonic cell 
growth. The growth of P. aeruginosa was followed until a Klett OD of ~40 was reached. 
CORM-2 (5 - 100 μM) (A) and colistin (1 - 4 μg/ml) (B) were then added to the cultures 
and readings taken at regular intervals. The control was adding DMSO (40 μl) alone to 




Figure 3.11 The effect of combined colistin and CORM-2 treatment on P. aeruginosa 
planktonic cell growth.  The growth of P. aeruginosa was followed until a Klett OD of 
~40 was reached. The combination of CORM-2 (5 - 10 μM) and colistin (2 μg/ml) was 
then added to the cultures and readings taken at regular intervals. The control was adding 
DMSO (40 μl) alone to the cultures. Values are an average of four biological samples 
with the respective SE. 
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3.2.3.4 The effect of combined CORM-2 and colistin treatment on P. aeruginosa 
established biofilms 
Following the demonstration that CORM-2 or colistin alone inhibits P. aeruginosa 
planktonic cells, it was hypothesized that the combination of two antimicrobial agents 
may also inhibit the growth of P. aeruginosa biofilms. To investigate this, a 24 h mature 
biofilm was generated on the MRD removable plugs. Plugs containing biofilms from the 
MRD were moved to a petri dish containing CORM-2 (30 μM) or colistin (4 μg/ml) alone 
or a combination of two antimicrobial agents. The petri dishes were then incubated in 37 
°C non-shaking incubator for 2.5 h. The plugs were removed from petri dishes to 10 ml 
PBS to evaluate the number of viable sessile bacteria in the biofilm by measuring the 
colony-forming units per cm2 (Figure 3.12). The effects of CORM-2 (30 μM) and colistin 
(4 μg/ml) on P. aeruginosa established biofilm cells were not significant (p>0.05). 
Meanwhile, the combination of effects from CORM-2 and colistin was also indifferent 
against P. aeruginosa established biofilm cells. This data clearly demonstrate that 
CORM-2 does also not enhance the activity of colistin against P. aeruginosa biofilm 
cells. 
 
3.2.3.5 The Interaction between CORM-2 and colistin 
To investigate the interaction between CORM-2 and colistin, the FIC was evaluated by a 
checkerboard method (see section 2.2.6). It is clear that the MIC of CORM-2 alone is 
3.84 μg/ml, while MIC of colistin alone is 4 μg/ml. The MIC of CORM-2 in combination 
was reduced to the 1.92 μg/ml, while the MIC of colistin in combination was reduced to 
2 μg/ml (Table 3.1). According to the equations in section 2.2.6, FIC for CORM-2 is 
calculated as 0.5, FIC for colistin is calculated as 0.5, so the summation of FIC index is 




Figure 3.12 The effect of combined colistin and CORM-2 treatment on P. aeruginosa 
established biofilms.  A 24 h P. aeruginosa biofilm was generated on the MRD. CORM-
2 (30 μM), colistin (4 μg/ml) or the combination of two antimicrobial agents was applied 
directly to the biofilm cells in separate petri dishes for 2.5 h. The number of viable sessile 
bacteria in the biofilm was evaluated by measuring the colony-forming units per cm2. 
Each value shows an average of three biological samples with the respective SE.  
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Table 3.1 MICs of CORM-2 and colistin to the P. aeruginosa PAO1. 
 
 MIC (μg/ml) 






3.84 4 1.92  2 
𝐹𝐼𝐶(𝐶𝑂𝑅𝑀 − 2) =
𝑀𝐼𝐶(𝐶𝑂𝑅𝑀 − 2 𝑖𝑛 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛)












∑𝐹𝐼𝐶 = 𝐹𝐼𝐶(𝐶𝑂𝑅𝑀 − 2) + 𝐹𝐼𝐶(𝑐𝑜𝑙𝑖𝑠𝑡𝑖𝑛) = 0.5 + 0.5 = 1 
0.5 < ∑𝐹𝐼𝐶 < 4 𝑖𝑠 𝑖𝑛𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡  
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3.2.4 The potential protective mechanisms in P. aeruginosa biofilms against CORM-
3 
3.2.4.1 Anaerobic microenvironment 
In the biofilm, oxygen concentration is reduced at the base. The presence or absence of 
oxygen is known to modulate action of the antibiotic aminoglycosides (Tack and Sabath, 
1985). Bacteria in an anaerobic region of a biofilm may be differentially protected from 
these antibiotics, even if they are capable of fermentative growth. To understand how P. 
aeruginosa cells behave under anaerobic conditions, cultures were grown in anaerobic 
M9 medium. 8 ml cell culture were grown in Klett-compatible 8.5 ml screw-cap tubes at 
200 rpm 37 °C incubator. CORM-3 was added directly to the growing cultures when a 
Klett OD of ~40 was reached. The Klett OD was recorded using a Klett meter every 2 h 
(Figure 3.13). Lower concentrations of CORM-3 (10 - 100 μM) did not stop P. 
aeruginosa planktonic cell growth under anaerobic condition. To completely prevent the 
growth of P. aeruginosa anaerobic culture a higher concentration (200 μM) was required. 
 
3.2.4.2 Starvation-induced tolerance 
In the laboratory, bacteria become highly resistant to antibiotics when nutrients are 
limited in the media (Nguyen et al., 2011). Nguyen and co-workers have found the 
starvation-induced stringent response is a determinant of biofilm-specific antimicrobial 
resistance in P. aeruginosa, because inactivation of this protective mechanism greatly 
sensitizes P. aeruginosa biofilms to various classes of antibiotics and markedly enhances 
the efficacy of antibiotic treatment in experimental infections of P. aeruginosa. 
 
To estimate if the starvation in the biofilm would affect CORM-3 uptake, a starter culture 
was grown overnight in 20 ml LB medium and cells pelleted by centrifugation; the pellet 
was then resuspended in 20 ml aerobic M9 medium with 20% glucose to replace LB. This 




Figure 3.13 The effect of CORM-3 on anaerobic P. aeruginosa planktonic cells 
growth. P. aeruginosa anaerobic planktonic cell culture was grown in anaerobic M9 
medium in a screw-cap tube. CORM-3 was added to growing culture when a Klett OD of 
~40 was reached. Data shows the mean and standard deviation from 2 biological 
replicates.  
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fresh M9 medium with 20% glucose. The cells were grown in 37 °C shaking incubator 
until an OD600 of ~0.5 was reached, then stressed with 30 μM CORM-3 for 2 h. The 
optical densities at 600 nm, cell viability and uptake of ruthenium by P. aeruginosa cells 
were measured over a time-course with samples taken at t=0, 10, 30, 60, 120 minutes 
after addition of CORM-3 (30µM) (Figure 3.14A, B, C). The cells were actively growing 
with glucose supplement. Cells were completely killed by CORM-3 (30 μM) after 1 h. 
Ruthenium was continuously accumulated by cells during 2 h treatment. 
 
To compare with actively growing cells as described above, a starter culture was grown 
overnight in 20 ml LB medium; it was then centrifuged and replaced with 20 ml M9 
medium with 20% glucose before inoculation to a flask containing 180 ml fresh M9 
medium with glucose. The cells were grown in 37 °C shaking incubator until an OD600 of 
~0.5 was reached, then centrifuged and replaced with 200 ml M9 medium in the absence 
of glucose for 2.5 h. The starved culture was then centrifuged again and replaced with 
200 ml PBS containing 30 μM CORM-3 to provide no nutrient to the cells for 2 h. The 
optical densities at 600 nm, cell viability and uptake of ruthenium by P. aeruginosa cells 
were measured over a time-course with samples taken at t=0, 10, 30, 60, 120 min after 
addition of CORM-3 (30µM) (Figure 3.14D, E). Cells were energy-starved after 2.5 h 
treatment without glucose. However, a higher concentration of ruthenium was detected 
in cells. This may be because starved cells cannot export CORM-3 after accumulating 
CORM-3 inside. Meanwhile, only a small amount of viable cells (<108 CFU ml-1) was 
detected in a viability assay (data not shown). 
 
3.2.4.3 The penetration of CORM-3 through P. aeruginosa exopolysaccharide 
The biofilm matrix can act as a barrier to delay the diffusion of antibiotics into biofilms 
because antibiotics may either react chemically with biofilm matrix components or attach 
to anionic polysaccharides (Stewart, 1996). A major component of exopolysaccharide 
matrix produced by P. aeruginosa is alginate (Olvera et al., 1999). In order to examine 
the role of exopolysaccharide in CORM-3 penetration, the sodium alginate was used to 
model the Pseudomonas exopolysaccharide in this study. Two different volumes of 
alginate gel (240 μl and 600 μl) layer were placed on a membrane filter in a culture plate 
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insert (see Figure 2.5). A volume of 50 μl of CORM-3 (30 μM) was added to the gel and 
incubation was done at room temperature for 24 h, after which ruthenium concentration 
in the water was measured (Figure 3.15). A significant reduction in ruthenium 
concentration was detected with increasing alginate thickness. It is clear alginate gel acted 
as a protection layer from CORM-3 penetration. This is reflected by the data shown in 
section 3.2.2, in which P. aeruginosa biofilm cells are less sensitive to CORM-3 
compared to planktonic cells.  
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Figure 3.14 The P. aeruginosa planktonic cell growth under glucose starvation. Cell 
growth with glucose supplement was recorded by measuring OD600 (A), Ruthenium 
uptake (B) and cell viability (C). Cell growth under glucose starvation was recorded by 
measuring OD600 (D) and Ruthenium uptake (E). Data shows the mean and standard 




Figure 3.15 Penetration of CORM-3 through two different volumes of alginate gel. 
CORM-3 (30 μM) was penetrated through two different volumes of alginate gel. Samples 
were taken after 24 h to measure the ruthenium concentration. Data shows the mean and 
standard deviation from 2 biological replicates of which there were 4 technical repeats.  
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3.3 Discussion 
The bactericidal effect of ruthenium-based CORMs on numerous bacteria had been 
reported when the work described in this thesis was undertaken, including E. coli 
(Davidge et al., 2009b, McLean et al., 2013, Nobre et al., 2007, Wilson et al., 2013), C. 
jejuni (Smith et al., 2011), S. enterica serovar Typhimurium (Rana et al., 2014) and P. 
aeruginosa (Desmard et al., 2009, Desmard et al., 2012). Although Desmard’s group 
have found CORM-3 to be bactericidal against a laboratory strain of P. aeruginosa 
planktonic cells, P. aeruginosa is extremely hard to treat due to this organism’s high 
ability to produce biofilm. Therefore, P. aeruginosa biofilm mode of growth is the main 
focus in current presented work. Murray and his co-workers published the first report on 
the effect of CORM-2 on P. aeruginosa biofilms. In that study, CORM-2 not only killed 
planktonic cells but also attenuated P. aeruginosa biofilm formation and established 
biofilms. However, the details of the effect of CORM-3 on P. aeruginosa and how 
CORM-3 works on P. aeruginosa biofilm remained elusive. Thus, the work presented in 
this chapter firstly investigated the effect of CORM-3 on P. aeruginosa planktonic cells 
with the aim of learning preliminary information about the laboratory strain used in this 
study. The possibility of using CORM work as an adjuvant is also discussed in this 
chapter. 
 
3.3.1 The effect of CORM-3 on P. aeruginosa cells in vitro 
The work presented in this chapter first shows that CORM-3 has an inhibition effect on 
P. aeruginosa planktonic cell growth in a concentration-depended manner (Figure 3.3A). 
CORM-3 is bactericidal when given to planktonic cells at a concentration of 30 μM 
(Figure 3.4). The finding that the control solution (CO-saturated solution) does not 
significantly inhibit growth of P. aeruginosa planktonic cells (Figure 3.3B) suggests that 
the CORM-3 molecule is the agent causing the inhibition, rather than CO alone. This 
finding was in agreement with Desmard’s group (Desmard et al., 2009). As shown in this 
study and by others, the effect of CORM compounds is not mimicked by equimolar 
concentrations of CO; CO gas is surprisingly ineffective in inhibiting microbial growth 
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(Wegiel et al., 2014) and has been shown to be much less effective than CORMs in 
inhibiting bacterial growth (Nobre et al., 2007). 
 
Furthermore, we have shown that CORM-3 prevents P. aeruginosa biofilm maturation 
and kills cells within the established P. aeruginosa biofilm (Figure 3.6 and Figure 3.9). 
CORM-3 did not completely kill all P. aeruginosa biofilm cells at a concentration of 30 
μM after 2.5 h treatment. However, in P. aeruginosa planktonic cell studies, CORM-3 
completely killed P. aeruginosa planktonic cells at 30 μM. This indicates biofilm 
formation does protect P. aeruginosa cells from the bactericidal effect of CORM-3. 
 
3.3.2 The effect of CORM-2 on P. aeruginosa cells in vitro 
CORM-2 was examined in these initial experiments to provide more information about 
the effect of ruthenium-based CORMs on P. aeruginosa cells. Murray and co-workers 
showed that CORM-2 killed P. aeruginosa planktonic cells as early as 30 min, with a 
minimal growth inhibitory concentration of 10 μM (Murray et al., 2012).  
 
In agreement with Murray’s report, the planktonic cells studies presented in this chapter 
shows both CORM-2 and colistin have an antimicrobial effect on P. aeruginosa 
planktonic cells (Figure 3.10). In comparison to CORM-3 studies, CORM-2 was more 
inhibit on P. aeruginosa planktonic cell growth than the same concentration of CORM-
3. This finding was also supported by Nobre and co-workers, who found that higher 
concentrations of CORM-3 than CORM-2 were required to reduce the cell viability in E. 
coli and S. aureus cultures (Nobre et al., 2007). 
 
The combination of CORM-2 and colistin study shows CORM-2 does not enhance the 
activity of colistin against P. aeruginosa planktonic cells (Figure 3.11). It is clear that 
CORM-2 combined with colistin had inhibitory effects on bacterial growth. However, 
compared with the inhibitory effect of CORM-2 or colistin on P. aeruginosa planktonic 
cells (Figure 3.10), the combination effect of CORM-2 and colistin was not synergistic 
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against P. aeruginosa planktonic cells. Therefore, the addition of CORM-2 did not 
enhance the activity of colistin. This finding is further confirmed by the FIC result (Table 
3.1), which shows the interaction between CORM-2 and colistin is indifferent. 
Meanwhile, the data presented in Figure 3.12 clearly demonstrate that CORM-2 does also 
not enhance the activity of colistin against P. aeruginosa biofilm cells. 
 
3.3.3 Biofilm growth methods 
Two different methods were developed to examine P. aeruginosa biofilm growth in this 
chapter. One is the microtitre plate method, which is a quick and efficient way to evaluate 
the biofilm growth. The benefit of the microtitre plate assay is that it is possible to grow 
planktonic and biofilm populations simultaneously (in each well) under different 
conditions (in each plate) and semi-quantitatively measures their relative growth. 
However, this method has been criticized because of the inability of crystal violet to 
differentiate between living and dead cells, and between cells and matrix material (Peeters 
et al., 2008). Another concern about this method is that there is no standard protocol for 
this method, and different groups use different concentrations of inoculum, biofilm 
incubation times, dye concentrations and staining times. The other method used in this 
chapter is the Modified Robbins Device method, which is a relatively simple way to 
generate the biofilm, but requires a specialised apparatus. The benefit of this device is 
that biofilm cells can easily be removed from the device for quantitation or examination 
after the biofilm formation, and this device is able to study both young and mature 
biofilm. However, the major issue with this device was that the bactericidal efficiency 
varied on different plugs. 
 
It is clear that the P. aeruginosa biofilms were successfully formed on the surface of the 
MRD. However, in the Nickel (1985) experiment, the mature biofilms on the catheter 
material reached around 2.7 x 109 CFU/cm2 after colonization is completed at 12 h. 
Compared to the result shown in Figure 3.7, Nickel’s group has formed about 10-fold 
more biofilm cells. Therefore, the future improvement for generating more P. aeruginosa 
biofilm on the MRD can be investigated.  
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3.3.4 The potential protective mechanisms in P. aeruginosa biofilms against CORM-
3 
It is clear that P. aeruginosa biofilm cells are more resistant to CORM-3 compared to 
planktonic cells (See section 3.2.2). In order to understand the mechanisms behind this 
activity, three hypotheses were assessed. 
 
Firstly, the aerobic microenvironment inside the biofilm was initially considered to be 
one of the major causes of P. aeruginosa biofilm tolerance to CORM-3. Previous data 
have demonstrated that CORM-3 completely inhibits the growth of P. aeruginosa aerobic 
cultures at a concentration of 100 μM (Figure 3.3 and Figure 3.5). However, to prevent 
the growth of P. aeruginosa anaerobic culture, a higher concentration (200 μM) was 
needed (Figure 3.13). Therefore, P. aeruginosa anaerobic cultures are more resistant to 
CORM-3 compare to aerobic cultures. It implies the anaerobic microenvironment in the 
P. aeruginosa biofilm could contribute to protect the biofilm cells from CORM-3 
bactericidal effect. Hassett’s group has found under strict anaerobic conditions, P. 
aeruginosa increased producing alginate, which formed a barrier for it to resistant to 
antimicrobial agents (Hassett, 1996). Meanwhile, Davidge and co-workers have also 
reported that anaerobic E. coli cultures have been shown to be susceptible to killing by 
high concentrations of CORM-3 (Davidge et al., 2009b). 
 
Another hypothesis for the resistance seen with CORM-3 on P. aeruginosa biofilms is 
that the starvation in the biofilm could induce the tolerance towards the antimicrobial 
effect of CORM-3. However, the data presented in Figure 3.14 disproved the original 
hypothesis. CORM-3 is accumulated to a greater extent in energy-starved cells than 
actively growing cells. This indicates that starvation stress in the P. aeruginosa biofilm 
does not contribute to CORM-3 tolerance. This may due to the limitation of nutrient, cell 
membrane are more vulnerable for CORM-3 to permeate into the cells. 
 
The last hypothesis assessed in this chapter is if the P. aeruginosa biofilm extracellular 
matrix could act as a barrier to protect P. aeruginosa cells from CORM-3. In order to 
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understand whether this was the case, the infusion of CORM-3 through Pseudomonas 
exopolysaccharide alginate gel was examine. Less CORM-3 was detected with increasing 
the volume of alginate gel (Figure 3.15). This finding indicates alginate is able to delay 
the infusion of CORM-3. Therefore, P. aeruginosa biofilm extracellular matrix may 
contribute to the resistance against CORM-3. 
 
3.3.5 Conclusions 
CORM-3 rapidly kills planktonic cells of a P. aeruginosa laboratory strain (PAO1). 
Although CORM-3 is effective at inhibiting surface-associated growth of P. aeruginosa 
by both preventing biofilm maturation and killing bacteria within the established biofilm, 
cells growing in a biofilm are more resistant to CORM-3 than planktonic cells. Poor 
penetration and anaerobic microenvironment may contribute to this resistance, but not 
starvation. Similarly, bactericidal activity of CORM-2 is confirmed in P. aeruginosa 
planktonic cells. Although CORM-2 or colistin kills bacteria within the established 
biofilm, the combination effect of those two antimicrobial compounds is found to be 









Chapter 3 revealed that P. aeruginosa biofilms could be successfully formed on the 
surface of the MRD. However, in order to conduct nebuliser studies of P. aeruginosa 
biofilms, it is important to be able to harvest a large number of cells. For this reason, this 
chapter aims to grow cells continuously in a chemostat system rather than under batch 
conditions. 
 
A chemostat is a culture in which fresh medium is introduced, while a mixture of spent 
medium and cells is removed at the same rate. Although the practice of adding fresh 
medium to a growing bacterial culture had been discussed before 1950, it was the work 
of Jacques Monod that first revealed that, by using a chemostat culture, it is possible to 
control the growth rate of a bacterial population. Chemostat theory was developed by the 
ground-breaking theoretical work of John Pirt in the 1970s (Pirt, 1975). The main 
advantage to the use of a chemostat is that it is possible to maintain the growth of the 
population at a set rate, i.e. in a steady state. Steady state is defined as the state of the 
population at which growth rate is equal to the dilution rate. Thus the population is kept 
at a constant density by virtue of controlling the concentration of a limiting nutrient. The 
second advantage to using a chemostat is that it is possible to maintain a long-term culture 
of cells that are growing in relatively defined and controlled conditions. 
 
Chemostat culture is not without its limitations. Growth rate can only be controlled by 
dilution rate up to the point at which cells are washed out of the system. Additionally 
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limiting nutrients will result in a population undergoing starvation responses and reduced 
growth rates, resulting in gene regulation and increased rates of mutation (Ferenci, 2008). 
 
4.1.2 Inhalation therapy for P. aeruginosa infections in the CF lung 
It was discussed in Chapter 1 that current treatments for P. aeruginosa infections in the 
CF lung include oral and parenteral antibiotics, and especially the inhaled nebulized 
antibiotics. The advantages of inhalation therapy for P. aeruginosa infections in the CF 
have been highlighted for over 45 years (Mearns, 1970). This therapy is a highly effective 
way to treat lung disease especially, since it can maximize the dose at the location of the 
disease instead of systemic exposure, toxic to the rest of the body. In UK, the majority of 
patients are treated with twice daily colistin or tobramycin solution for inhalation. The 
latter drug is administered on a one month on/one month off regimen (Castellani et al., 
2018). 
 
Colistin is a member of the polymyxin group. It was initially used therapeutically in the 
1950s (see (Kumazawa and Yagisawa, 2002) for a survey) but was abandoned due to the 
reported high incidence of nephrotoxicity in the early 1980s (Brown et al., 1970). 
However, the emergence of multidrug-resistant Gram-negative bacteria and the shortage 
of new antimicrobial agents have brought back the interest of using colistin as a valuable 
therapeutic option. There is increasing research with the use of aerosolized colistin in P. 
aeruginosa infections in cystic fibrosis (Jensen et al., 1987, Hodson et al., 2002, Berlana 
et al., 2005, Herrmann et al., 2010). 
 
With the emergence of bacteria resistant to most commercially available antibiotics and 
advances in the discovery of novel antibiotic compounds, novel antimicrobial agents that 
could replace or complement current therapies are needed to fight chronic infections in 
CF patients. Recently, there have been numerous studies on the therapeutic effects of 
CORMs (Motterlini and Otterbein, 2010, Romao et al., 2012). However, these researches 
have only focused on studies using growing cultures of bacteria in liquid culture. The 
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effectiveness of CORMs when applied as aerosols suitable for treating infections is still 
unknown. 
 
4.1.3 The aim of this work 
This chapter aims to apply nebulized controlled doses of CORMs to P. aeruginosa cells. 
By monitoring bacterial viability and the uptake of CORMs, we will assess the potential 
of this nebuliser therapy for treating P. aeruginosa related infections with CORMs. The 
work described in this chapter used CORM-3 as a model CORM as it is chemically well 
characterised and is water-soluble, a property that is important for the nebulizer treatment. 
Colistin, which is widely used antibiotic in chronic P. aeruginosa infections, was used in 
order to compare the efficacy of CORM-3 and colistin.  
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4.2 Results 
4.2.1 Development of methods to grow biofilm 
4.2.1.1 Cultivation of P. aeruginosa planktonic cells in batch culture 
To determine a suitable time point for further experiments, a time course was initially 
conducted in which P. aeruginosa PAO1 planktonic cells were grown in M9 medium for 
48 h in a chemostat vessel (Figure 4.1). The pH changes were detected by a pH meter. 
The residual glucose was also measured (see section 2.2.3), and the optical density of the 
planktonic cells growth was also recorded. It was found that the bacterial cells reached 
stationary phase after 24 h and the doubling time was 2.1 h. To maintain stable pH in the 
fermenter vessel, the concentration of phosphates in the medium was increased (see 
section 2.1.2.2). The pH in the fermenter vessel decreased over time. The glucose was 
effectively used by P. aeruginosa planktonic cells during the bacterial growth, and had 
run out after 24 h. As cells would eventually be grown in a chemostat at steady state by 
limiting the carbon source, 30 h was selected for trial in the chemostat to start a continuous 
growth. 
 
4.2.1.2 Cultivation of P. aeruginosa biofilm cells in continuous culture 
In order to harvest a maximum yield of P. aeruginosa biofilm cells, cultures were grown 
in a chemostat as described in section 2.1.5.7 and Figure 2.3. An overnight starter culture 
of P. aeruginosa PAO1 was inoculated into 125 ml M9 medium (4 % inoculum). P. 
aeruginosa planktonic cells were grown as a batch culture for 30 h until it was switched 
to a continuous culture. The cell growth was determined by measuring the optical density 
every hour after switching to a continuous culture (Figure 4.2A). The pH changes in the 
chemostat system were detected by a pH meter (Figure 4.2B). The glucose assay was 
used to measure the glucose changes during bacterial growth (Figure 4.2C). It is clear 
from Figure 4.2 that the optical density of the P. aeruginosa planktonic cells decreased 
after switching to a continuous culture, but seemed to be stable after 48 h. Meanwhile, 
the pH stayed in an optimal range. Glucose was sufficient in the chemostat vessel during 










Figure 4.1 Growth of P. aeruginosa planktonic cells in the chemostat vessel operated 
as a batch culture. P. aeruginosa was grown in the chemostat vessel containing M9 
medium for 48 h. The optical density at 600 nm (A), pH changes (B) and glucose changes 










Figure 4.2 Growth of P. aeruginosa planktonic cells in the chemostat vessel operated 
as a continuous culture. P. aeruginosa was grown in the chemostat vessel containing 
M9 medium for 30 h before switching to a continuous culture. The optical density at 600 
nm (A), pH changes (B) and glucose changes (C) were measured at 30 h time point (•). 
Data were also recorded for a further 24 h.  
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not the limiting component for growth. However, this is an advantage for the MRD 
protocol, since the glucose carried over can support an initial phase of growth on the 
MRD plugs. 
 
The P. aeruginosa biofilm populations were generated on the MRD connected to this 
continuous culture. The cultures were initially allowed to grow in the chemostat vessel as 
a batch culture for 30 h with a stir rate of 100. After this time, the stir rate was increased 
to 260 and the medium flow was started at 30 ml h-1. After the cultures were pumped 
through the MRD for a further 72 h, aerobically grown biofilm-associated cells were 
harvested on the MRD and ready for analysis. A 2 ml sample was also taken at the 
entrance or the end of the MRD to test the OD600 and glucose limitation (Figure 4.3). To 
check for glucose limitation, samples were subjected to a glucose assay. The optical 
density was increased after cultures flow through the MRD. Meanwhile, the glucose 
concentration was significantly decreased after cultures flow through the MRD. One 
additional experiment was conducted by not supplying glucose to fresh medium after 
switching to continuous culture. The optical densities were the same at the entrance and 
the end of the MRD over time. 
 
4.2.2 Applying CORM-3 and colistin to P. aeruginosa cells by an aerosol method 
4.2.2.1 The effect of CORM-3 and colistin administered by the nebuliser on P. 
aeruginosa agar-grown cells  
The initial design of the experiment was to convert CORM-3 solution and colistin 
solution into a mist which can be applied to P. aeruginosa cells, as outlined in section 
2.1.5.8.  The first task was to form a uniform plate contains P. aeruginosa cells. The 
uniform plate was made according to section 2.1.8. Agar plate cell circles were then taken 
with a 4 mm borer before inserting into the sampling ports. 20 ml of CORM-3 (310 μg/ml) 
or colistin (500 μg/ml) solution was converted into the mist and sprayed on the agar plate 
cell circles for 10 min treatment. The viabilities of these cell circles were compared to the 
circles without the treatment. Treatment with 500 μg/ml colistin reduced the viability of 







Figure 4.3 Growth of P. aeruginosa biofilm cells on the MRD that connected to a 
continuous culture. P. aeruginosa was grown aerobically as batch-culture for 30 h in the 
chemostat vessel. It was then switched to continuous-culture and pumped through the 
MRD for biofilm formation. Samples were taken at the entrance and the end of the MRD 
for measuring the optical density changes (A) and the glucose changes (B).  
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after 10 min (Figure 4.4). Similarly, treatment with 310 μg/ml CORM-3 decreased the 
viability of P. aeruginosa agar plate cells to 42% of the untreated control after 10 min 
(Figure 4.5). 
 
4.2.2.2 The effect of CORM-3 and colistin administered by the nebuliser on P. 
aeruginosa biofilm cells  
In order to compare the effect of aerosolized CORM-3 on P. aeruginosa biofilm cells 
with aerosolized colistin, biofilm cells were formed on the MRD connected to a 
continuous culture, as described in section 4.2.1.2. After 72 h generation, P. aeruginosa 
biofilm cells were formed on the sampling plugs on the MRD. These removable sampling 
plugs were easily detached from the MRD and inserted into the pipeline in the aerosol 
system (Figure 2.5). Solutions (20 ml) of CORM-3 (310 μg/ml) or colistin (500 μg/ml) 
solution were converted into mist and sprayed on the biofilm cell plugs for 10 min. The 
viabilities of cells on these plugs were compared to the plugs without the treatment. 
Treatment with 500 μg/ml colistin reduced the viability of P. aeruginosa biofilm cells to 
30% of the untreated control after 10 min (Figure 4.6). Similarly, treatment with 310 
μg/ml CORM-3 decreased the viability of P. aeruginosa biofilm cells to 35% of the 
untreated control after 10 min (Figure 4.7). The large standard deviation in these data 
highlights the high variability in biofilm grown on the MRD. 
 
4.2.2.3 Analysis of CORM-3 concentration in P. aeruginosa biofilm cells after 
treatment 
In order to demonstrate the uptake of aerosolised CORM-3 by the P. aeruginosa biofilm 
cells, assays for the presence of ruthenium were conducted using ICP-MS (see section 
2.3.1). In brief, this technique relies on mass spectrometry to detect levels of trace metals 
in samples.  
 
P. aeruginosa biofilm cells were formed on the MRD, then stressed with CORM-3 (310 
μg/ml) for 10 min in the aerosol system as described in the section above. The treated P. 




Figure 4.4 Effect of aerosolized colistin on the P. aeruginosa agar plate cells. P. 
aeruginosa agar plate cells were formed on a uniform plate. The cell circles were inserted 
into the aerosol system. Colistin (500 μg ml-1) was sprayed on the cells for 10 min before 
counting the number of viable cells. The bars represent the cell viability before and after 
treatment with colistin. Data shows the mean and standard deviation from 5 technical 




Figure 4.5 Effect of aerosolized CORM-3 on the P. aeruginosa agar plate cells. P. 
aeruginosa agar plate cells were formed on a uniform plate. The cell circles were inserted 
into the aerosol system. CORM-3 (310 μg ml-1) was sprayed on the cells for 10 min before 
counting the number of viable cells. The bars represent the cell viability before and after 
treatment with CORM-3. Data shows the mean and standard deviation from 5 technical 





Figure 4.6 Effect of aerosolized colistin on the P. aeruginosa biofilm cells. P. 
aeruginosa biofilm cells were generated on the MRD before moving to the aerosol 
system. Colistin (510 μg ml-1) was sprayed on the cells for 10 min before counting the 
number of viable cells. The bars represent the cell viability before and after treatment 
with colistin. Data shows the mean and standard deviation from 5 technical repeats (* 




Figure 4.7 Effect of aerosolized CORM-3 on the P. aeruginosa biofilm cells. P. 
aeruginosa biofilm cells were generated on the MRD before moving to the aerosol 
system. CORM-3 (310 μg ml-1) was sprayed on the cells for 10 min before counting the 
number of viable cells. The bars represent the cell viability before and after treatment 
with CORM-3. Data shows the means and standard deviations from 5 technical repeats 
(* means p<0.05). 
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centrifuging the cell mixtures, the cell pellets were washed with dilute HNO3 three times 
prior to digestion with concentrated acid and subjected to an ICP-MS assay. Raw values 
for ruthenium levels were obtained, and intracellular concentrations were calculated 
(Table 4.1). There was a mean of 0.99 μg ruthenium detectable inside the P. aeruginosa 
biofilm cell pellets from two biological repeats. 
 
 
4.2.2.4 The interaction between CORM-3 and colistin 
To investigate the interaction between CORM-3 and colistin, the FIC was evaluated by a 
checkerboard method (see section 2.2.6). It is clear the MIC of CORM-3 alone is 4.65 
μg/ml, while MIC of colistin alone is 4 μg/ml. The MIC of CORM-3 in combination was 
reduced to 2.3 μg/ml, while the MIC of colistin in combination was reduced to 2 μg/ml 
(Table 4.2). According to the equations in section 2.2.6, FIC for CORM-3 is calculated 
as 0.5, FIC for colistin is calculated as 0.5, so the summation of FIC index is calculated 
as 1, which implies the interaction between CORM-3 and colistin is indifferent.  
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Table 4.1 Results of two biological repeats from ICP-MS analysis. 
 
 Measured Ruthenium amount (μg) 
PBS 
supernatant 















Table 4.2 MICs of CORM-3 and colistin to the P. aeruginosa PAO1. 
 
 MIC (μg ml-1) 










4.3.1 Use of custom built chemostat 
The presented work revealed the difference between grown P. aeruginosa cells in a batch 
culture and continuously in a chemostat system. In the batch culture, glucose was 
effectively used by P. aeruginosa cells and ran out after 24 h. Since glucose is the sole 
carbon source in the medium, the yield of P. aeruginosa cells could not be maximized. 
In the chemostat culture, dilution rate, nutrient limitation and pH were all controlled or 
monitored. However, one major problem that appeared in this experiment was the 
reduction of the optical density in the initial 24 h flow period. The reasons are still 
unknown. Factors might include correct flow rate, stable culture temperature and oxygen 
level etc. Firstly, the correct flow rate was checked through a calculation. The specific 
growth rate (μ) was measured from Figure 4.1 as 0.3 h-1; to keep a steady growth rate, the 
dilution rate (D) should be equal to the required growth rate, D is therefore equal to 0.3 
h-1. From this, the flow rate (F) can be calculated for a given vessel volume (V, which is 
125 ml) and is 37.5 ml h-1 (F = D × V). The actual flow rate was used in this experiment 
is 30 ml h-1, which is optimal. Secondly, the temperature was monitored by a real-time 
thermometer, which showed to be in 37-38 °C. Oxygen level inside the chemostat vessel 
was not measured. 
 
The importance of glucose in P. aeruginosa biofilm growth was determined in section 
4.2.1.2. P. aeruginosa biofilm cells used most glucose in the medium during biofilm 
formation (Figure 4.3). When glucose was not supplied to the medium, P. aeruginosa 
biofilm cells stopped forming. 
 
4.3.2 Applying CORM-3 and colistin to P. aeruginosa cells by an aerosol method 
With the development of inhaler therapy, which allows medicines to be delivered in the 
form of a mist through the lung, it is interesting to test if CORM-3 could be successfully 
applied to P. aeruginosa cells by an aerosol method. We have shown that aerosolized 
CORM-3 had a significant effect on the viability of both P. aeruginosa agar plate cells 
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and biofilm cells (Figure 4.6 and Figure 4.8). In comparison to colistin, a commonly used 
nebulized antibiotic for CF lung infections, aerosolized colistin also caused a significant 
decrease on P. aeruginosa cell viability. 
 
The ICP-MS results confirmed CORM-3 was taken up by P. aeruginosa biofilm cells. 
Although the mechanism of CORM-3 bactericidal activity against P. aeruginosa biofilms 
is still unknown, but with this finding, P. aeruginosa biofilm cells accumulate CORM-3 
inside may be a key factor. Recent evidences have shown the antimicrobial effects of 




It is more favourable to grow P. aeruginosa cells continuously in a chemostat system 
rather than under batch condition. Glucose is essential in the growth of P. aeruginosa 
biofilm. Aerosolized CORM-3 treatment has a similar bactericidal effect to aerosolized 
colistin. Although CORM-3 or colistin kills P. aeruginosa cells, the combination effect 





Interaction of P. aeruginosa with PhotoCORM 
 
5.1 Introduction 
5.1.1 The antimicrobial effect of PhotoCORM 
Numerous CORMs have been studied against bacteria. In previous chapters, ruthenium-
based CORMs were studied with P. aeruginosa planktonic and biofilm cells. It was 
revealed that although CORM-3 inhibits surface-associated growth of P. aeruginosa by 
both preventing biofilm maturation and killing bacteria within the established biofilm, 
cells growing in a biofilm are more resistant to CORM-3 than planktonic cells. Recent 
evidence has shown that the ruthenium co-ligand fragment of the CORMs exerts 
significant biological impacts. Therefore, newer CORMs that lack ruthenium may be 
desirable for future studies. 
 
One class of particular interest are CORMs that release CO when exposed to a specific 
wavelength and intensity of light, called PhotoCORMs (photoactivatable carbon 
monoxide-releasing molecules) (Schatzschneider, 2011). PhotoCORM must be stable in 
the dark in order for the compound to accumulate in target tissues prior to photoexcitation, 
after which CO will be released, and ideally will not rebind to a high degree, but rather 
bind a solvent molecule in order to stabilise the remaining molecule. Recently, a 
manganese-based PhotoCORM has been described that has therapeutic potential (Ward 
et al., 2012). Particular advantages of this CORM are that it releases 3 CO molecules 
from each CORM molecule, is activated by light from a LED (light emitting diode) at 
400 nm, and is not toxic to RAW 264.7 murine macrophages before and after irradiation. 
 
The compound used in this chapter is a novel water-soluble PhotoCORM ([Mn(CO)3(tpa-
κ3N)]Br), which is stable in the dark whereas releases CO to myoglobin only on 
illumination at 365 nm (Nagel et al., 2014). Antimicrobial activity of this compound was 
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shown against E. coli K-12 only after irradiation. Pronounced inhibition of cultures 
growing in the presence of a non-fermentable carbon source upon activation of the 
PhotoCORM in situ, together with the demonstration of CO binding to E. coli terminal 
oxidases suggested that the mechanism of action of PhotoCORM is related to the 
inhibition of respiration more than the toxicity exerted by the metal-coordinated backbone 
(Nagel et al., 2014). 
 
5.1.2 The aim of the work 
The advance of PhotoCORM-CN028-31 is using manganese as the CO carrier. In 
compare to ruthenium, manganese is more biological favourable. Manganese is a 
naturally occurring element in biology and so it is not toxic at moderate concentrations to 
bacteria. This chapter aims to investigate the antibacterial activity of this new Mn-based 
PhotoCORM ([Mn(CO)3(tpa-κ3N)]+) against P. aeruginosa planktonic and biofilm cells. 
It was hypothesised that P. aeruginosa planktonic cells would be more sensitive to Mn-
based CORMs than biofilm cells.  
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5.2 Results 
5.2.1 Effect of PhotoCORM and CO-saturated solution on the growth of P. 
aeruginosa planktonic cell 
To investigate the antimicrobial action of PhotoCORM on P. aeruginosa PAO1, 
planktonic cultures of P. aeruginosa PAO1 growing in M9 medium were stressed with 
increasing concentrations of PhotoCORM prior to the exposure to 6 min UV light and 
incubated for 24 h, as described in section 2.1.5.9. Addition of 100 μM PhotoCORM 
failed to produce inhibitory effects during the first 10 h of growth. Slight inhibition of the 
growth was evident in cultures containing 200 μM activated PhotoCORM while higher 
concentrations (up to 500 μM) caused severe retardation of the growth for ~ 10 h followed 
by partial recovery (Figure 5.1). On the other hand, cultures treated with 500 μM 
PhotoCORM but not exposed to UV grew similarly to cultures exposed to UV light in the 
absence of PhotoCORM. Therefore UV exposure, and presumably CO release, was 
essential for growth inhibition. 
 
In addition, a CO-saturated solution (see section 2.1.3.2) was used as a control solution 
to test the effect of CO alone on the growth of P. aeruginosa planktonic cells. The cell 
cultures were treated with PhotoCORM (0, 300 μM) or CO-saturated solution (1 mM CO) 
followed by 2 min exposure to UV light (365 nm). No inhibition effects were observed 
in cultures stressed with PhotoCORM (300 μM) or CO-saturated solution without 
exposure to UV when compared to cultures exposed to UV light in the absence of 
PhotoCORM (Figure 5.2). 
 
5.2.2 Effect of PhotoCORM and CO-saturated solution on P. aeruginosa biofilm 
formation 
Since UV light itself has antimicrobial activity, an experiment was conducted to 
determine the maximum UV exposure that failed to cause detrimental effects on the 
biofilm formation of P. aeruginosa. Plates containing 200 μl PAO-1 cultures were 




Figure 5.1 Effect of PhotoCORM in the growth of P. aeruginosa planktonic cells. 
Cultures were grown in M9 medium at 37 °C, 200 rpm. A range of PhotoCORM (0–500 
μM) was added to cultures (2.5 ml) followed by 6 min exposure to UV light (365 nm). 





Figure 5.2 Effect of PhotoCORM or CO-saturated solution on P. aeruginosa 
planktonic cells. PhotoCORM (0, 300 μM) or CO-saturated solution (1 mM) was added 
to cultures (200 μl) followed by 2 min exposure to UV light (365 nm). The control was 
cultures treated with 300 μM PhotoCORM and kept in the dark. Data shows the means 
and standard deviations from 5 technical repeats.  
 120 
37 °C to promote biofilm formation and biofilm biomass was determined by the crystal 
violet assay. Cultures exposed to UV light for up to 2 min showed no differences with 
respect to unexposed controls while 3 min or more slightly diminished the biomass 
(Figure 5.3). Therefore, an illumination time of 2 min was chosen for further biofilm 
studies. 
 
The biofilm formation from PAO-1 cultures was severely compromised by the presence 
of 200 μM PhotoCORM and only small differences were observed with further increased 
concentrations of the compound (Figure 5.4A). The toxicity was clearly related to the 
activation of the PhotoCORM by exposure to UV, since cultures containing unexposed 
PhotoCORM (500 μM) and untreated control cultures produced comparable amounts of 
biomass (Figure 5.4A). Interestingly, the negative effect of activated PhotoCORM on the 
PAO-1 biofilm formation was similar to that observed by the presence of 8 μg/ml colistin 
(MIC of colistin for PAO-1 cells is 4 μg ml-1, as seen in Chapter 3), and the antibiotic 
known by its ability to effectively damage P. aeruginosa biofilms (Figure 5.4A). In 
addition, biofilm formation was not affected by the presence of CO-saturated solution (1 
mM), which indicated it is the compound that causes inhibition (Figure 5.4B). 
Intriguingly, the viability of biofilm-forming cells was slightly decreased by the presence 
of either activated and no activated PhotoCORM. However, differences were not 
significant compared to the untreated control (Figure 5.5). The slight effect might be 
related to direct damage to initial planktonic cells in early biofilm formation phase, and 
this would consequently impair their ability to produce the biofilm. Corresponding to the 
data shown in Figure 5.4, the clear effect of activated PhotoCORM on preventing the 
formation of biofilm may be caused not only by killing initial planktonic cells but also 
interrupting biofilm formation. 
 
5.2.3 Effects of PhotoCORM and CO-saturated solution on P. aeruginosa biofilm 
maturation 
To further explore whether activated PhotoCORM had any direct effects on damaging 




Figure 5.3 Effect of exposure to UV light on P. aeruginosa biofilm formation. A liquid 
culture grown overnight was aliquot (200 μl each) into the wells of a 96-well plate. Each 
plate was irradiated with UV light for different period of time. After 48 h incubation at 
37 °C non-shaking incubator, the biofilm biomass was measured with a crystal violet 









Figure 5.4 Effect of PhotoCORM on the P. aeruginosa biofilm formation. Cultures 
were grown on a 96-well plate at 37 °C non-shaking incubator. After 48 h incubation, the 
cell biomass was measured with crystal violet assay. In (A), a range of PhotoCORM (0–
500 μM) and colistin (4-8 μg/ml) were added to cultures followed by 2 min exposure to 
UV light (365 nm) before inoculated on the plate. The control was cultures added with 
500 μM PhotoCORM and kept in the dark. Data shows the means and standard deviations 
from 5 technical repeats. In (B), PhotoCORM (0, 300 μM) and CO-saturated solution (1 
mM) were added to culture followed by 2 min exposure to UV light (365 nm) before 
inoculated on the plate. The control was cultures treated with 300 μM PhotoCORM and 
kept in the dark. Data shows the means and standard deviations from 2 biological 





Figure 5.5 Effect of PhotoCORM on the viability of P. aeruginosa biofilms. Cultures 
were grown on a 96-well plate at 37 °C non-shaking incubator. A liquid culture grown 
overnight was aliquot (200 μl each) into the wells of a 96-well plate. PhotoCORM (0, 300 
μM) was added to cultures followed by 2 min exposure to UV light (365 nm). The control 
was a culture treated with 300 μM PhotoCORM and kept in the dark. After 48 h 
incubation, the number of viable cells was counted as CFU ml-1. Data shows the means 
and standard deviations from 3 technical repeats.  
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the presence of PhotoCORM was investigated (Figure 5.6). After promoting the 
formation of immature biofilms by 24 h static incubation at 37 °C, the culture medium 
was removed from the plates and replaced with fresh medium. Then, biofilms were 
exposed to UV for 2 min upon addition of increasing concentration of PhotoCORM and 
incubated for an additional 24 h to promote biofilm maturation (Figure 5.6A).  With 
supplementation of sufficient nutrients from fresh medium, the biofilm maturation was 
successful which resulted in doubling the amount of biofilm at 48 h time point. Activation 
of 200 μM PhotoCORM significantly inhibited the biofilm maturation to the same extent 
as colistin (8 μg ml-1), while 300 μM PhotoCORM or more not only produced inhibition 
but also effectively reduced the biomass of the immature biofilm (Figure 5.7A). Again, 
addition of PhotoCORM without UV activation, UV exposure in the absence of 
PhotoCORM or addition of CO gas failed to produce any detrimental effects (Figure 
5.7B). Activation of 300 μM PhotoCORM significantly reduced the amount of preformed 
biofilm compared to the biomass at 24 h time point, which is in agreement with data 
shown in Figure 5.4, activated PhotoCORM interrupted the biofilm formation. 
Meanwhile, the viability of biofilm cells was significantly decreased by the presence of 
activated PhotoCORM after 24 h when compared to either medium contains inactivated 
PhotoCORM or the untreated control as early as 1 h (Figure 5.8). This contributed to the 
inhibition of activated PhotoCORM in biofilm maturation as well. 
 
In a separate experiment, to further investigate the direct effect of activated PhotoCORM 
on PAO-1 established biofilm, after promoting the formation of immature biofilms by 24 
h static incubation at 37 °C, the culture medium was replaced with PBS buffer (instead 
of fresh medium), which could stop the growth and more clearly determine the disruption 
of the biofilm. Then, biofilms were exposed to UV for 2 min upon addition of increasing 
concentration of PhotoCORM and incubated for additional 24 h to interact with 
established biofilm (Figure 5.6B). With supplement pre-formed biofilm with PBS 
stopped the biofilm maturation during 24 h treatment. Loss of the biomass upon 24 h 
incubation in the presence of activated PhotoCORM was still observed (Figure 5.9A). 
This suggests activated PhotoCORM directly disrupt the PAO-1 biofilm structure. 
However, this effect was less pronounced (compare Figure 5.7A with 5.9A). 
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Figure 5.6 Process of investigating the effect of PhotoCORM on biofilm maturation. 
Cultures were grown on a 96-well plate at 37 °C non-shaking incubator for 24 h. In (A), 
M9 medium contains PhotoCORM, colistin or CO-saturated solution was added to 
cultures followed by 2 min exposure to UV light (365 nm) at 24 h time point. The control 
was cultures treated with PhotoCORM and kept in the dark; In (B), PBS containing 
PhotoCORM, colistin or CO-saturated solution was added to cultures followed by 2 min 
exposure to UV light (365 nm) at 24 h. The control was cultures treated with PhotoCORM 
and kept in the dark. In both experiments, after a further 24 h incubation, the cell biomass 








Figure 5.7 Effect of PhotoCORM on the P. aeruginosa biofilm maturation. Cultures 
were grown on a 96-well plate at 37 °C non-shaking incubator for 24 h. In (A), M9 
medium contained a range of PhotoCORM (0–500 μM) or colistin (4-8 μg/ml) was added 
to cultures followed by 2 min exposure to UV light (365 nm) at 24 h. The control was 
wells treated with 500 μM PhotoCORM and kept in the dark. In (B), M9 medium contain 
PhotoCORM (0, 300 μM) or CO-saturated solution (1 mM) was added to culture followed 
by 2 min exposure to UV light (365 nm) at 24 h time point. The control was cultures 
treated with 300 μM PhotoCORM and kept in the dark. In both experiments, after a 
further 24 h incubation, the cell biomass was measured with a crystal violet assay. Data 
shows the means and standard deviations from 2 biological replicates of which there were 




Figure 5.8 Effect of PhotoCORM on the viability of established P. aeruginosa 
biofilms. Cultures were grown on a 96-well plate at 37 °C non-shaking incubator for 24 
h. M9 medium contains PhotoCORM (0, 300 μM) was added to cultures followed by 2 
min exposure to UV light (365 nm) at 24 h time point. The control was cultures added 
with 300 μM PhotoCORM and kept in the dark. After a further 24 h incubation was 
carried out. The number of viable cells was recorded as CFU ml-1 at regular time intervals. 







Figure 5.9 Effect of PhotoCORM on the established P. aeruginosa biofilm in PBS. 
Cultures were grown on a 96-well plate at 37 °C non-shaking incubator for 24 h. In (A), 
PBS contains a range of PhotoCORM (0–500 μM) or colistin (4-8 μg ml-1) was added to 
cultures followed by 2 min exposure to UV light (365 nm) at 24 h time point. The control 
was cultures added with 500 μM PhotoCORM and kept in the dark; In (B), PBS contains 
PhotoCORM (0, 300 μM) or CO-saturated solution (1 mM) was added to culture followed 
by 2 min exposure to UV light (365 nm) at 24 h time point. The control was cultures 
added with 300 μM PhotoCORM and kept in the dark. In both experiments, after a further 
24 h incubation, the cell biomass was measured with crystal violet assay. Data shows the 
means and standard deviations from 2 biological replicates of which there were 5 
technical repeats (* means p<0.05).  
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5.3 Discussion 
5.3.1 Summary of this study 
The work in this chapter constitutes the first investigation of the effect of this novel 
PhotoCORM ([Mn(CO)3(tpa-κ3N)]+) on any biofilm. PhotoCORM is a water-soluble 
CORM that releases CO only upon illumination at 365 nm. In addition, Mn was used as 
the metal core of this compound, which makes it more favourable in biological systems 
than Ru. 
 
In this study we demonstrate that activated PhotoCORM has only a slight effect on 
planktonic cultures of P. aeruginosa (Figure 5.1A). In comparison with previous 
ruthenium-based CORM studies (Figure 3.2 and Figure 3.9), the effect of activated 
PhotoCORM on the growth is mild. In addition, we have shown that activated 
PhotoCORM causes a loss of P. aeruginosa biofilm biomass during biofilm formation 
(Figure 5.3A). However, activated PhotoCORM is not bactericidal against P. aeruginosa 
biofilm cells during the formation (Figure 5.4). This suggests activated PhotoCORM 
inhibits the formation of P. aeruginosa biofilm without directly killing P. aeruginosa 
cells. 
 
Furthermore, it was shown that activated PhotoCORM inhibits the biofilm maturation 
and disrupts pre-formed biofilm on conditions where cells are metabolically active 
(Figure 5.5A and Figure 5.7A). However, PhotoCORM has only a discrete effect on the 
disruption of biofilm during starvation. Activated PhotoCORM is more potent to P. 
aeruginosa biofilm cells than planktonic cell, which makes this compound an ideal 
candidate for further studies of treating infections related to P. aeruginosa biofilms. The 
effect of activated PhotoCORM on P. aeruginosa biofilms shows that it is more effective 
on P. aeruginosa biofilms than colistin. The finding that CO-saturated solution does not 
inhibit the growth of P. aeruginosa planktonic cultures and biofilm cultures (Figure 5.1B, 
5.3B, 5.5B and 5.7B) suggests that the effect on growth of PhotoCORM can be attributed 
to the compound as a whole and not CO alone.  
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5.3.2 The benefit of Manganese in PhotoCORM 
The PhotoCORM used in this study is a Mn based compound. It has not been investigated 
in this study whether the manganese from PhotoCORM has a protective effect on cells. 
However, the possibility that manganese may play a protective role in cells has reported 
by several research groups. It was first arose in studies of Lactobacillus plantarum which 
survives on Mn-rich fermenting plant materials (Archibald and Duong, 1984). Not only 
was it shown that this bacterium accumulated manganese to exceedingly high levels, it 
was also shown that the bacterium exhibited a Mn(II)-dependent superoxide dismutase 
activity that was inhibitable by EDTA (Archibald and Fridovich, 1982). Additionally, in 
Deinococcus radiodurans, a bacterium known for its resistance to ionizing radiation (Cox 
and Battista, 2005, Slade and Radman, 2011), accumulation of manganese is tolerated to 
levels as high as 30 mM (Daly et al., 2004). It is thought that the high manganese content 
of cells is associated with non-enzymatic reactions that protect the organism from reactive 
oxygen species (Slade and Radman, 2011, Horsburgh et al., 2002). For example, such 
activities include Mn(II) carbonate which exhibits catalase-like activity (Berlett et al., 




In summary, activated PhotoCORM exhibits only slight inhibition of the growth of P. 
aeruginosa planktonic cultures. However, activated PhotoCORM prevents and disrupts 
biofilm formation of P. aeruginosa but non-illuminated PhotoCORM is without effect. 
Activated PhotoCORM inhibits biofilm maturation and disrupts pre-formed biofilms. 
Activated PhotoCORM, but not CO gas, produces toxic effects in both planktonic 







The beneficial effects of CO have led the research to CORMs. The therapeutic properties 
of CORMs then led researchers to investigate their effect on P. aeruginosa in the past 
two decades. Before the work was examined in this thesis, CORMs were mainly applied 
to P. aeruginosa planktonic cells. In planktonic culture, CORM-3 was bactericidal to both 
a laboratory strain (PAO1) and three clinical isolates of P. aeruginosa (Desmard et al., 
2009). Murray and colleagues were the first to evaluate the effects of CORM-2 on P. 
aeruginosa biofilm maturation and surface colonization. They have shown that CORM-
2 (25 - 200 μM) prevented biofilm maturation as early as 60 min after addition. CORM-
2 (100 μM) also decreased the number of viable bacteria recovered from the biofilm as 
early as 30 min after treatment, and persisting for a further 6 h. With the development of 
CORMs, the work presented in this thesis therefore sought to dissect the effect of both 
CORM-2 and CORM-3 on P. aeruginosa planktonic cells with biofilm cells (see Chapter 
3). Bactericidal activity of both CORM-2 and CORM-3 were confirmed in P. aeruginosa 
planktonic cells. Although CORM-3 was effective at inhibiting surface-associated growth 
of P. aeruginosa by both preventing biofilm maturation and killing bacteria within the 
established biofilm, cells growing in a biofilm were more resistant to CORM-3 than 
planktonic cells. Poor penetration and anaerobic microenvironment may contribute to this 
resistance, but not starvation. In study of CORM-2 as potential adjuvant compound with 
colistin, the combination effect of those two antimicrobial compounds was found to be 
indifferent against P. aeruginosa planktonic cells and biofilm cells. 
 
In order to harvest enough P. aeruginosa biofilm cells to establish the role of CORM-3 
in biofilm cell killing, grew cells continuously in a chemostat system rather than under 
batch conditions was carried out (see Chapter 4). In our studies, it was more favourable 
to grow P. aeruginosa cells continuously in a chemostat system rather than under batch 
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condition. Interestingly, glucose was detected to be a key factor in the growth of P. 
aeruginosa biofilm. Furthermore, aerosolized CORM-3 treatment had a similar 
bactericidal effect to aerosolized colistin on P. aeruginosa cells. Although CORM-3 or 
colistin killed P. aeruginosa cells separately, the combination effect of those two 
antimicrobial compounds was found to be indifferent against P. aeruginosa cells. 
 
A final avenue of exploration in this thesis was studying a new arising CORM: 
PhotoCORM. To date, little work has been done on the effect of PhotoCORM on bacteria, 
yet antimicrobial activity of PhotoCORM against a pathogenic E.coli has been already 
been shown by our group (Tinajero-Trejo et al., 2016). The research presented in this 
thesis for the first time highlighted the effect of PhotoCORM on P. aeruginosa cells (see 
Chapter 5). The activated compound proved to be as effective at bacterial killing as 
previously used ruthenium CORMs (such as CORM-2 and CORM-3). Overall, activated 
PhotoCORM prevented and disrupted biofilm formation of P. aeruginosa but non-
illuminated PhotoCORM was without effect. Activated PhotoCORM inhibited biofilm 
maturation and disrupted pre-formed biofilms. Activated PhotoCORM, but not CO gas, 
produced toxic effects in both planktonic cultures and biofilms of P. aeruginosa. 
 
6.2 Further scope and investigation 
6.2.1 Chemostat 
In this P. aeruginosa biofilm study, the chemostat is a valuable tool for bacterial 
cultivation (Chapter 3). However, it is impossible to grow biofilms in a completely steady 
state, an advantage of biofilm cultivation in a chemostat is long-term control of growth 
conditions, medium input rate and any extraneous variable to which the researcher may 
wish to profile a response. As fresh medium is constantly introduced, the chemostat 
allows the growth of mature biofilms, providing sufficient material for global analysis. It 
is also possible to use any growth surface, providing it can be attached to the inside of the 
chemostat, and allow growth of biofilm at the medium/air interface. The biofilm is not 
subject to a constant unidirectional laminar flow, and approximate shear forces can be 
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increased without the need to change the medium input rate. A disadvantage is that it is 
not possible to make direct observations of the biofilm in situ. 
 
6.2.2 Transport of CORMs 
A challenging, but essential area of research is the transport of CORMs into bacterial 
cells. Robert’s group has proposed a ‘‘Trojan Horse’’ mechanism for the antimicrobial 
actions of CO-RMs to explain the potent effects on respiration that cannot be mimicked 
by CO gas (Figure 6.1). In brief, a CORM may lose its CO permanently in the 
extracellular milieu through, for example, the presence of a species to capture the CO or 
a change in the CO-RM after CO loss. Alternatively, the CORM is transported into the 
cell and concentrated carrying its CO cargo (Trojan Horse effect), and CO dissociation is 
promoted by a reaction with intracellular ligands that include sulphite. Thus, CO is 
immediately accessible at relatively high concentrations to membrane-bound heme 
targets, to which it binds. Respiration is inhibited in a light-reversible manner, and 
viability is drastically reduced (Wilson et al., 2013). 
 
The movement of CORMs into cells in this study is measured indirectly through the 
detection of the metal species within cells using ICP-MS (details see section 2.2.7). 
However, it is more difficult to determine the fate of the CORM sub-cellularly once it has 
been taken up into cells. One method that may help to overcome this issue is radioisotope-
labelling the metal species of CORMs. Not only could radiolabelling help to generate 
accurate uptake kinetics but may also reveal the breakdown products of the metal co-
ligand species of the compound or where the co-ligand species may bind to other proteins.  
Another method that may show sub-cellular localization of the compounds is through 
electron microscopy imaging. If the heavy metal is localized to one place within the cell, 
heavy metal deposits will be visible after staining, but if the metal species is distributed 
throughout the cell it may be more challenging to see. 
 
6.2.3 CORMs as potential adjuvant compounds 
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Figure 6.1 Trojan Horse hypothesis. It is postulated that CO- RMs carry their CO 
‘‘toxic cargo’’ into the cell interior by unknown mechanisms. Intracellular accumulation 
of CO- RMs and subsequent release of CO leads to CO reaching concentrations (center 
of cell) that exceed those which can be attained by passive diffusion of CO gas from the 
cell exterior (bottom left). The major targets of CORM-3 identified in this work are 
respiratory electron transfer to O2, catalyzed by terminal quinol oxidases, and cation 
transport. Inhibition of respiration and growth inhibition is reversed by white light at 
ambient temperatures (top right). The scheme excludes the bacterial outer membrane 
and periplasm and the representation of the respiratory chain, terminating in a single 
oxidase, is greatly simplified (Wilson et al., 2013).   
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Concerns over the inevitable spread of established antibiotics to treat antibiotic-resistant 
‘superbugs’ has been widely explored. Meanwhile, advances in the discovery of novel 
antibiotic compounds has been slow. A solution to these problems could be to develop 
CORMs as adjuvants to existing antibiotic compounds. It has currently been counseled 
that combination therapy involving non-antibiotic adjuvants should offer a more realistic, 
long-term approach in controlling rising drug resistance (Brooks and Brooks, 2014). 
CORMs have already proven promise in combination therapy in a range of animal 
models. Murray and colleagues were the first to find CORM-2 acts as an adjuvant to 
tobramycin against P. aeruginosa biofilms (Murray et al., 2012). Work published by 
Tavares’s group showed sub-lethal doses of CORM-2 were combined with 
metronidazole, amoxicillin and clarithromycin and found strongly reducing the ability of 
H. pylori to infect macrophages, and also reducing the viability of cells(Tavares et al., 
2013). Wareham and co-workers determined the MICs of three well- established 
antibiotics (TR, DC, and CT) where CORM-2 was used in agar plates. In their study, 
CORM-2 led to dramatic reduction in MICs of those three antibiotics (Wareham et al., 
2016). A novel manganese CORM, CORM-401, in combination with cefotaxime and 
trimethoprim was showed to reduce bacterial growth of E. coli later around by the same 
group (Wareham et al., 2018).  
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